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ABSTRACT 
 
Transcriptional Regulation of Pregnane X Receptor by Protein Arginine 
Methyltransferase.  
Ying Xie, B.S., Peking University 
Chair of Advisory Committee: Dr. Yanan Tian 
 
Pregnane X receptor (PXR) is a ligand-dependent transcription factor that plays an 
important role in xenobiotic/drug metabolism. The ligand-receptor interaction 
transcriptionally activates phase I and phase II enzymes, and membrane-bound 
transporters in a coordinated manner and ultimately leads to detoxification and excretion 
of the ligands. One of the direct target genes is cytochrome P450 3A4 (CYP3A4) which 
is responsible for metabolism of over 50% of clinically used drugs. Understanding the 
regulation of PXR is important for treatment of disease and avoidance of untoward drug-
drug interactions.  
In this research, we have used various biochemical and molecular approaches to 
investigate factors that regulate the transcriptional activity of PXR. We have stably 
transfected PXR into HepG2 human liver hepatoma cells. Using these PXR-HepG2 
cells, we surveyed the histone methyltransferases that interact with PXR.  Based on 
results from co-immunoprecipitation/methyltransferase, N-terminal peptide sequencing, 
GST-pulldown assays, we found that protein arginine methyltransferase 1 (PRMT1) is a 
predominant histone methyltransferase in HepG2 cells.   
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Evidence from other laboratories suggests that histone methylation by PRMT1 sets 
the stage for subsequent histone modifications such as the acetylation of histone H4. 
These modifications are believed to be important for transcriptional and epigenetic 
regulation of gene expression. We hypothesize that PRMT1 plays a role in the epigenetic 
changes regulated by PXR. PRMT1-dependent histone methylation changes may be 
involved in epigenetic cell memory where prior exposure to certain agents may alter the 
chromatin (or priming the chromatin) with a “primed” state which alters the subsequent 
magnitude or duration of gene expression.  
In our study, we have found that pretreatment of PXR-HepG2 cells with DMSO 
greatly enhanced PXR-mediated activation of CYP3A4 upon rifampicin treatment. 
DMSO pretreatment altered histone modifications association with the promoter of the 
PXR-regulated gene (CYP3A4). Inhibition of histone methylation by PRMT1 either 
through RNAi or the methyltransferase inhibitor (Adox) abolished the priming effects.    
My research results strongly indicate that PRMT1 is involved in transcriptional 
regulation of PXR and may be involved in epigenetic memory of liver cells where prior 
exposure to agents changes the subsequent detoxification responses. 
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CHAPTER I 
INTRODUCTION 
 
1.1 NUCLEAR RECEPTOR 
1.1.1 Nuclear receptor subfamilies 
Nuclear receptors are a superfamily of ligand-activated transcription factors that 
regulate important physiological functions, such as drug metabolism, development, cell 
differentiation, and reproduction (1-5) . They are specific for animals, but not in other 
species (6). There are 270 nuclear receptors in C. elegans (7), while in human, there are 
only 48 (8). 
Evans divided nuclear receptors into three classes based on their dimerization and 
DNA binding properties (9). Class I includes the steroid hormone receptors, including 
progesterone receptor (PR), estrogen receptor (ER), glucocorticoid receptor (GR), 
androgen receptor (AR), and the mineralocorticoid receptor (MR). Upon ligand binding, 
they dissociate from heat shock proteins, translocate into the nucleus, and bind cognate 
response elements as homodimers. Response elements for class I receptors are always 
inverted repeats, for example, 5′-AGAACAnnnTGTTCT-3′ (10).  
The thyroid/retinoid receptors, including the thyroid receptor (TR), vitamin D 
receptor (VDR), retinoic acid receptor (RAR), and the peroxisome proliferator activated 
receptors (PPARs) are the second class of nuclear receptors (11). Thyroid/retinoid 
 
____________ 
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receptors typically bind as heterodimers with RXR to direct repeats, such as                           
AGGTCA(N)4AGGTCA (12). In the absence of agonist, corepressor proteins bind the 
heterodimers to prevent gene expression. After agonist binding, corepressor proteins 
dissociate from the receptor, and coactivators are recruited for activation of transcription 
(13,14). 
The third class orphan nuclear receptors typically have no known endogenous 
ligands at time of their identification (15,16). Recent studies have identified ligands for 
several orphan receptors, and these are adopted orphan receptors, which include liver X 
receptor (LXR), pregnane X receptor (PXR), and farnesol X receptor (FXR) (17-19). 
Some orphan nuclear receptors bind response elements as heterodimers with RXR (20), 
and some bind as monomers or homodimers. The everted repeat, such as 
TGAACT(N)6AGGTCA, is another motif recognized by these receptors (21), and Table 
1.1 lists the ligand, expressing tissue, response elements and target genes for some 
nuclear receptors.  
The nuclear receptors are also divided 7 subfamilies for their formal nomenclature; 
subfamily 0-6, and listed in Table1.2 which follows (22).   
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Table 1.1. Nuclear Receptors – ligand, response element, target genes 
Target genes NR Ligands Response 
element 
Tissue 
Phase I Phase II Phase III 
CAR Androgens, 
phenobarbital, 
rifampicin 
DR-3, DR-4, 
DR-5, ER-6 
Liver, 
intestine, 
kidney 
CYP2A6, 
CYP2B1, 
CYP2B6, 
CYP2C9, 
CYP2C19 
 
UGT1A1 ABCC2, 
ABCC3, 
ABCC4 
SXR/PXR Bile acids, 
steroids, 
rifampicin, 
phenobarbital, 
clotrimazole 
DR-3, DR-4, 
DR-5, ER-6, 
ER-8 
Liver, 
intestine 
CYP1A2, 
CYP2B6, 
CYP2C9, 
CYP2C19, 
CYP3A4, 
CYP3A7, 
CYP7A1(-), 
CYP3A 
SULT2A1
, 
UGT1A1, 
UGT1A3, 
UGT1A4 
ABCA1, 
ABCB1, 
ABCB11, 
ABCC1, 
ABCC2, 
ABCC3, 
ABCG2 
FXR Bile acids IR-1, DR-1 Liver CYP7A1(-), 
CYP8B1(-) 
UGT2B4, 
SULT2A1 
ABCB4, 
ABCB11, 
ABCC2 
LXRα,β Oxysterols DR-4 Liver, 
intestine, 
kidney 
CYP2B6(-), 
CYP3A4(-) 
 ABCA1, 
ABCG1, 
ABCG4, 
ABCG5, 
ABCG8 
PPARα Fatty acids, 
prostaglandins, 
leukotrienes, 
Fibric acids, 
phthalate esters 
DR-1 Liver, 
intestine, 
kidney 
CYP4A1, 
CYP4A3, 
CYP7A 
UGT1A9, 
UGT2B4 
ABCA1, 
ABCC2, 
ABCD2, 
ABCD3 
PPARδ Fatty acids, 
carboprostacyclin 
  CYP4A UGT1A ABCA1 
PPARγ Eicosanoids, 
thiazolidinediones 
  CYP4AB UGT1A9 ABCA1, 
ABCG2 
RXRα Retinoic acids  Liver, 
intestine, 
kidney 
CYP2B6  ABCB1, 
ABCG4 
VDR 1α,25-dihydroxy 
vitamin D3
DR-3, ER-6, 
IR-0 
Liver, 
intestine 
CYP2B6, 
CYP2C9, 
CYP3A4 
SULT2A1 ABCC2 
 (-), down-regulation.  (23) 
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Table 1.2. Nuclear receptor subfamilies 
NR1 (Thyroid Hormone Receptor-like) 
Group A (Thyroid hormone receptor): TRα/NR1A1; TRβ/NR1A2 
Group B (Retinoid acid receptor): RARα/NR1B1; RARβ/NR1B2; RARγ/NR1B3 
Group C (Peroxisome proliferators-activated receptor): PPARα/NR1C1; PPARβ/δ/NR1C2;  
PPARγ/NR1C3 
Group D (Rev-ErbA): Rev-ErbAα/NR1D1; Rev-ErbAβ/NR1D2 
Group F (RAR related orphan receptor): RORα/NR1F1; RORβ/NR1F2; RORγ/NR1F3 
Group H (Liver X receptor-like): LXRα/NR1H3; LXRβ/NR1H2; FXR/NR1H4 
Group I (Vitamin D receptor-like): VDR/NR1I1; PXR/NR1I2; CAR/NR1I3 
NR2 (Retinoid X Receptor-like) 
Group A (Hepatocyte nuclear factor-4): HNF-4α/NR2A1; HNF-4γ/NR2A2 
Group B (Retinoid X receptor): RXRα/NR2B1; RXRβ/NR2B2; RXRγ/NR2B3 
Group C (Testicular receptor): TR2/NR2C1; TR4/NR2C2 
Group E: Human homologue of Drosophila tailless gene, TLX/NR2E1;  
        Photoreceptor cell-specific nuclear receptor, PNR/NR2E3 
Group F: Chicken ovalbumin upstream promoter transcription factor, COUP-TFI/NR2F1;  
COUP-TFII/NR2F2; V-erbA-related, EAR-2/NR2F6 
NR3 (Estrogen Receptor-like) 
Group A (Estrogen receptor): ERα/NR3A1; ERβ/NR3A2 
Group B (Estrogen-related receptor): ERRα/NR3B1; ERRβ/NR3B2; ERRγ/NR3B3 
Group C (3-Ketosteroid receptor): Glucocorticoid receptor, GR/NR3C1;  
Mineralocorticoid receptor, MR/NR3C2;  
Progesterone receptor, PR/NR3C3;  
Androgen receptor, AR/NR3C4 
NR4 (Nerve Growth Factor IB-like) 
Group A: Nerve growth factor IB, NGFIB/NR4A1; Nuclear receptor related 1, NURR1/NR4A2; 
        Neuron derived orphan receptor 1, NOR1/NR4A3 
NR5 (Steroidogenic Factor-like) 
Group A: Steroidogenic factor 1, SF1/NR5A1; Liver receptor homolog 1, LRH-1/NR5A2 
NR6 (Germ Cell Nuclear Factor-like) 
Group A: Germ cell nuclear factor, GCNF/NR6A1 
NR0 (Miscellaneous) 
Group B: Dosage sensitive sex reversal, adrenal hypoplasia critical region on chromosome X, gene 1, 
DAX1/NR0B1; Small heterodimer partner, SHP/NR0B2 
Group C: Nuclear receptors with two DNA binding domains, 2DBD-NR 
(24) 
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Subfamily 1 is the biggest family with 7 groups. This subfamily is called the 
thyroid hormone receptor-like receptors, and includes TRs, RARs, PPARs, LXR, VDR, 
PXR, and CAR. Subfamily 2 contains the retinoid X receptor-like receptors, HNF4, 
RXRs, and testicular receptors. Subfamily 3 contains the estrogen receptor-like 
receptors, including estrogen receptors, estrogen-related receptors, and ketosteroid 
receptors. Subfamily 4 composes the nerve growth factor IB-like receptors, subfamily 5 
contains steroidogenic factor-like receptors, subfamily 6 consists of germ cell nuclear 
factor-like receptors, and the last subfamily 0, is composed of miscellaneous receptors. 
1.1.2 Nuclear receptor structure 
Most nuclear receptors share a common modular structure which includes the N-
terminal ligand independent transcription activation function domain AF-1, the DNA 
binding domain (DBD), a flexible hinge region, and the C-terminal ligand binding 
domain (LBD) which contains AF2 (Figure 1.1) (25).  
The N-terminal AF1 domain is a structurally variable ligand-independent 
transactivation domain. Some studies showed that DNA-binding and protein-protein 
interactions can modulate AF1 conformation (26-28). The DBD of the nuclear receptors 
is composed of two highly conserved zinc fingers and is responsible for targeting a 
receptor-specific response element within regulatory regions of target genes (29,30). 
This helical globular domain is also responsible for dimerization (31). The function of 
the hinge region, which connects the DBD and LBD, is not clear. There is evidence that 
phosphorylation of this region increases transcriptional activation of some nuclear 
receptors (32,33).  
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The structure and function of the C-terminal LBD has been extensively 
investigated. This domain contains the ligand-binding site where specific xenobiotic or 
endogenous ligands bind and the conserved activation function-2 (AF-2) domain. Upon 
ligand binding, AF-2 recruits several coactivator proteins that facilitate chromatin 
remodeling and activation of the transcriptional machinery (14,34,35). The LBD is also 
critical for receptor dimerization and is required for higher affinity binding to response 
elements (36,37). 
 
 
N C
AF-1           DBD          H LBDAF-2
A/B                         C         D                E/F 
 
Figure 1.1. Nuclear receptor structural domains. AF, activation function; DBD, DNA binding domain; 
H, hinge region; and LBD, ligand binding domain. 
 
 
 
1.1.3 Nuclear receptor coregulators 
Most nuclear receptors, except those belonging to class I, regulate target genes 
based on exchange between corepressors and coactivators (coregulators are listed in 
Table 1.3 below) (13,14). In the absence of an agonist or in the presence of an 
antagonist, these nuclear receptors recruit corepressor complexes, such as nuclear 
receptor corepressor (NCoR) (38), silencing mediator of retinoic and thyroid hormone 
receptors (SMRT) (39), and Mi-2/NuRD complexes which exhibit both histone 
deacetylase and nucleosome dependent ATPase subunits that repress transcription 
(40,41). When nuclear receptors bind agonists, they undergo conformational changes, 
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resulting in the release of corepressor complexes and recruitment of coactivator 
complexes (36). More than 200 cofactors have been discovered and these include the 
p160 steroid receptor coactivator (SRC) family (35), histone modification enzymes (42), 
thyroid hormone receptor-associated proteins (TRAPs) (43), and other proteins. 
Coregulators with histone modification activity can also modify coactivators or even 
nuclear receptors and thereby regulate activation of the target genes. For example, p300 
can acetylate the hinge region of the estrogen receptor alpha and this regulates 
transactivation and hormone sensitivity of this receptor (44). 
Compared with corepressors, the structure and function of coactivators has been 
more extensively investigated. Coactivators play a role not only in histone modifications, 
chromatin remodeling and transcription initiation, but also in elongation, RNA splicing, 
and RNA maturation (45,46). Coactivators usually contain a LXXLL motif for binding 
with the nuclear receptor ligand binding domain (47). Histone modification enzymes are 
required to loosen the tight chromatin structure, and among coactivators, the SRC/p160 
family and the cyclic AMP response element-binding protein (CBP)/p300 proteins 
exhibit histone acetyltransferase (HAT) activity (48). Protein arginine methyltransferase 
4 (PRMT4/CARM1) and PRMT1 are both histone methyltransferases (HMTs) that are 
also nuclear receptor coactivators (49,50). ATP-dependent remodeling complexes such 
as SWI/SNF increase the chromatin accessibility (34,51); the positive transcription 
elongation factor (P-TEFb) plays a role in elongation (52); PGC-1 (peroxisome 
proliferator-activated receptor gamma coactivator-1), CAPER (coactivator of activating 
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protein-1 and estrogen receptors), and CoAA (an RRM-containing transcriptional 
coactivator) are important in mRNA splicing (45,53,54). 
 
 
Table 1.3. Nuclear receptor coregulators. 
COACTIVATORS 
Acetyltransferases 
CBP, p300, pCAF, GCN5, Tip60 
Interact with CBP/p300 
      SRC-1/NCoA1, GRIP1/TIF2/SRC2/NCoA2, CIP/RAC3/AIB1/ACTR/TRAM1/SRC3 
ATP-dependent chromatin remodeling complex 
      SWI/SNF/BRG1 
Methyltransferases 
      CARM1, PRMT1,  
TRAP/DRIP/ARC complex 
COREPRESSORS 
      NCoR, SMRT, LCoR 
(55) 
 
 
It has also been reported that modification of nuclear receptors and other 
coregulators is important for regulating gene transcription and these modifications 
include acetylation, methylation, phosphorylation, ubiquitination, SUMOylation and 
other modifications (42,56-61). Modifications of coregulators can influence multiple 
gene sets targeted by different nuclear receptors that interact with the modified 
coregulator. Table 1.4 lists coregulator modifications and functions of these 
modifications (62). 
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Table 1.4. Nuclear receptor coregulator modifications. 
Coregulator Modification Regulatory activity 
C-terminal binding protein 
1 
Phosphorylation Loss of repressor activity 
N-CoR Phosphorylation 
SUMOylation 
Ubiquitination 
Nuclear export  
Increased repressive activity  
Increased protein turnover 
PCBP1 (poly(rC) binding 
protein 1) 
Phosphorylation 
 
Loss of translational repression, conversion 
to a transcriptional coactivator, and control 
of alternative splicing  
PGC-1a 
 
Phosphorylation 
Methylation 
Acetylation 
Increased transcriptional activity 
Decreased transcriptional activity 
Decreased transcriptional activity 
RIP140 (receptor-
interacting protein 140) 
Vitamin B6 conjugation 
Phosphorylation  
Arginine methylation 
Increased repressive activity  
Increased repressive activity  
Loss of repressive activity 
SMRT (silencing mediator 
of retinoid and thyroid 
hormone receptors)
Phosphorylation Nuclear export 
 
SHARP (SMRT/HDAC1 
Associated Repressor 
Protein) 
Phosphorylation Increased transcriptional repression 
SRC-1 Phosphorylation Increased transcriptional activity 
SRC-2 Phosphorylation Increased transcriptional activity 
SRC-3 Phosphorylation  
 
Arginine methylation  
 
Acetylation 
Ubiquitination 
 
Increased transcriptional activity, 
transcription factor-dependent transcription 
Transcriptional dynamics, 
protein dissociation 
Protein dissociation 
Increased transcriptional 
activity and protein turnover 
(62) 
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In general, HAT containing coactivator complexes induce localized histone 
acetylation which is involved in gene activation. In addition to histone acetylation, 
coactivator SRC3 can by acetylated so that HAT-containing coactivator complexes 
dissociate and this results in decreased transactivation (63). Importin-α can be acetylated 
to regulate nuclear receptor translocalization (64); CBP/p300 can acetylate the nuclear 
receptor HNF-4 and prevent its transport from the nucleus to the cytoplasm (65). Other 
proteins, like p/CIP, AR and ERα can also be acetylated (66).  
Coactivator associated arginine methyltransferase 1 (CARM1) binds to p160 
proteins and synergistically activates target genes by methylating histone H3 (39). 
CBP/p300 can also be methylated by CARM1, and this modification suppresses the 
transcriptional activity of CBP/p300 (67) revealing the interplay between acetylation and 
methylation. Protein arginine methyltransferase 1 (PRMT1), another nuclear receptor 
coactivator that methylates histone H4 arginine 3 (H4R3) (50), can also methylate HNF-
4 to increase DNA binding and enhance the transactivation (68). CBP/p300 and p160 
proteins can be phosphorylated, and this also regulates their binding and interactions 
with other coregulators (69).  
Kinase-mediated phosphorylation also modifies NRs and coregulators and 
influences then effects on target gene transcription. A signal-regulated transactivation 
domain was found in CBP/p300 to be controlled by cAMP, and nuclear calcium and 
calcium/calmodulin-dependent protein kinase IV (70). PGC-1alpha was reported to be 
phosphorylated by p38 MAPK, resulting in dissociation of the coactivator from p160 
myb-binding protein (p160MBP), and loss of p160MBP-dependent repression (71).   
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The ubiquitin-proteosome system uses ubiquitin modifications to control protein 
levels. Poly-ubiquitinated proteins are subjected to degradation by proteosomes, while 
mono-ubiquitination is involved in transcriptional regulation rather than degradation, 
and mono-ubiquitinated proteins are stable (72). AR, PPARα, GR, RARγ, RXRα, and 
TRs are all regulated by the ubiquitin-proteosome system (73-77); and the nuclear 
receptor coregulator p300 has the ability to poly-ubiquitinate p53 protein (78).  
The small ubiquitin-related modifier (SUMO) is an ubiquitin-like molecule that 
plays a role in the localization and stabilization of coregulators (79). For example, a 
SUMO conjugating enzyme, Ubc9, can interact with AR, and SUMO E3 ligases were 
found to repress AR transactivation (80). Sumoylation can activate and stabilize GR 
(81,82) and SRC-1, GRIP1, and PR are all regulated by sumoylation (83,84). 
Sumoylated Elk-1 recruits HDAC2 to deacetylate histones (85); HDAC6 is recruited by 
sumoylated p300 (86) and sumoylation by SUMO E3 ligase RanBP2 also modifies 
HDAC4 deacetylase activity (87). 
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1.2 PREGNANE X RECEPTOR (PXR) 
1.2.1 PXR expression and structure 
The pregane X receptor (PXR) was identified as NR1I2, a member of the NR1I 
nuclear receptor subfamily, and plays an important role in xenobiotic responses. It was 
first discovered in mouse and human for its activation by various natural and synthetic 
pregnanes and was named PXR, SXR (steroid and xenobiotic receptor), and PAR 
(pregnane activated receptor) by different research groups (88-90). Later, its orthologs 
were cloned in rat, rabbit, and dog (17,91,92).  
The main tissues where PXR is expressed are the liver, small intestine, colon and 
kidney in human, rabbit, rat and mouse where CYP3A genes are induced (90,92-95). 
Other tissues also express low levels of PXR, such as lung, stomach, peripheral blood 
monocytes, blood-brain barrier, uterus, ovary, placenta, breast, osteoclasts, heart, adrenal 
gland, bone marrow and specific regions of the brain (93,96).  
Compared to its ligand-dependent transactivation, the regulation of PXR expression 
is less clear. PXR expression can be regulated by other nuclear receptors. Pascussi et al. 
reported that micromolar concentrations of the GR agonist dexamethasone can increase 
PXR mRNA levels in humans and mice and enhance CYP3A gene expression and the 
GR antagonist RU486 can block this effect (97). Another research group demonstrated 
that PXR expression is positively regulated by HNF4α (98). Two PPARα ligands, 
clofibrate and perfluordecanoic induce PXR expression in rat hepatocytes (92), 
indicating a regulatory role of PPARα on PXR. Pregnant mice express about 50-fold 
higher PXR in the liver and ovary than normal mice. This suggests that PXR expression 
 13
might be stimulated by pregnancy-induced endogenous hormones and it functions to 
protect the fetus or mother from xenobiotics or other endogenous toxic chemicals (94). 
Interleukin-6 (IL-6) was demonstrated as an inhibitor of PXR expression during the 
acute phase response in infections (99). In addition, chromatin structure, 
phosphorylation-dependent protein degradation, and cellular trafficking can also control 
PXR gene expression level (100-102).  
Subcellular localization of PXR is still controversial. Transfected human PXR 
localizes in the nucleus regardless of ligand treatment (103,104), and endogenous or 
injected mouse PXR in mouse liver was found localize in the cytoplasm and translocate 
into the nucleus upon ligand treatment (102,103). However, localization of the 
endogenous human PXR in primary hepatocytes has not been described.  
The human PXR gene consists of 9 exons and spans approximately 35kb of 
genomic DNA on chromosome 3q12-13.3. Three splicing variants were found to express 
different PXR isoforms (93). Only a few polymorphisms of CYP3A4 were identified 
and have little effect on CYP3A4 expression or function (105) However, 70 SNPs 
(single nucleotide polymorphisms) of PXR have been investigated (105-110), providing 
a good candidate molecular mechanism for the >50-fold inter-individual differences in 
CYP3A4 induction in human. However, although functional differences have been 
demonstrated among SNPs, they are not sufficient to predict all individual differences in 
drug metabolism. 
Although the overall domain arrangement of PXR is similar to other nuclear 
receptors, PXR can bind and is activated by a wide range of structurally diverse ligands. 
 14
The crystal structure of PXR LBD reveals several special features that distinguish it 
from other nuclear receptors. The volume of PXR ligand binding pocket is much bigger 
than other nuclear receptors. This is due to a 60-residue insertion unique to PXR which 
contains two additional β-strains (111-114). Crystal structure analysis demonstrated that 
PXR can expand highly mobile regions of its ligand binding pocket to fit large 
molecules such as rifampicin (111). Distinct from other nuclear receptors, the PXR LBD 
sequence is highly variable across species. This variability confers the diversity in 
response to different ligands (114) as discussed below. Some individual residues in the 
PXR LBD were critical for species-specific PXR transactivation (114-116).  
1.2.2 PXR ligands 
PXR can be activated by various pharmaceutical chemicals, environmental 
contaminants, dietary compounds, steroids, secondary bile acids, as well as several 
natural products. PXR LBD shares 70-80% identity across mammalian species, 
compared to 90% identity of other NR ligand binding domains and this is responsible for 
species-specific ligand activation profiles of PXR as well as species-specific CYP3A 
(cytochrome P450 3A) induction (114,117). CYP3A is a family of monooxygenases 
which exhibits phase I drug metabolizing enzyme activity (118). It was discovered that 
in different species, cytochrome P450 gene expression is induced differentially by 
known ligands (119) and these differences were, in part PXR-dependent. For example, 
rifampicin, an antibiotic that activates human and rabbit PXR and induces CYP3A4 
expression, has little effect on mouse or rat PXR (17). In contrast, the antiglucocorticoid 
pregnenolone 16-a-carbonitrile (PCN), the major agonist for mouse and rat PXR 
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activates CYP3A11 expression, but does not activate PXR in humans or rabbits 
(17,120,121). Humanized mouse which expresses human PXR in mouse is a very useful 
animal model in studying human PXR ligands (122). 
Human PXR can be activated by structurally diverse therapeutic chemicals. The 
PXR agonist first discovered are those that induce expression of cytochrome P450 3A 
(CYP3A) and include phenobarbital, metyrapone, clotrimazole, nifedipine, taxol, 
spironolactone, and trans-nonachlor (9,88,91,123-125). Other xenobiotics that activate 
PXR include ritonavir (the HIV protease inhibitor), tamoxifen, dexamethasone, 4-
hydroxytamoxifen, the antidiabetic agent troglitazone, SR12813,  bisphenol A, 
nonylphenol, and phthalic acid (17,120,126,127). 
In addition to these xenobiotics, PXR can also be activated by a variety of 
endogenous ligands (9,90,128,129). All PXR orthologs were reported to be activated by 
the progesterone metabolite 5β-pregnane-3,20-dione (130). Other pregnanes that activate 
PXR include pregnenolone for mouse PXR, progesterone and its 17α-hydroxylated 
derivative for rabbit PXR, and estradiol for human PXR (9,17,90). These findings are 
consistent with high expression of PXR during pregnancy and suggests a role for PXR in 
protecting the fetus from endogenous toxic steroids (94). Toxic bile acids that activate 
PXR include lithocholic acid (LCA) and its 3-keto metabolite. (131). In addition to 
protecting the body from xenobiotic toxicity, PXR also protects body against harmful 
effects of toxic endobiotics (132,133). 
The major natural products that activate PXR are St. John’s wort and vitamin E. St. 
John’s wort is an herb widely used for treatment of mild to moderate clinical depression 
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(134). Hyperforin, the major compound of St. John’s wort was demonstrated to be a 
potent natural agonist for PXR. It induces PXR transcriptional activation and recruitment 
of the coactivator SRC-1 (135,136). These data explain the reported adverse interactions 
between St. John’s wort and other prescription drugs (137). Among different forms of 
vitamin E, all four tocotrienols bind and activate PXR. However, tocopherols do not 
have this effect (138). In osteosarcoma cells, vitamin K2 activated PXR and other known 
PXR agonists induced the same bone markers as vitamin K2 (128). Other natural 
products that regulate PXR are reviewed by Staudinger et. al (139). 
Several PXR antagonists have recently been discovered. The marine-derived drug 
ecteinascidin 743 (ET-743) blocks activation of human PXR by SR12813 or paclitaxel, 
and the induction of PXR target genes CYP3A4 and MDR1 (multidrug resistance 
protein 1) (140). Some highly chlorinated polychlorinated biphenyls (PCBs), were found 
to antagonize human PXR, although PCBs are potent rodent PXR activators (141). 
Ketoconazole disrupts binding of the corepressor SMRT and coactivator SRC-1 with 
PXR (142) and ketoconazole analogues fluconazole and enilconazole inhibit paclitaxel-
induced PXR activation (143,144). Sulforaphane (SFN) is also a PXR antagonist (145). 
1.2.3 PXR target genes and functions 
Drug/xenobiotic metabolism consists primarily of three steps, known as phase I 
(oxidation), phase II (conjugation), and phase III (transportation) reactions. In phase I 
and II, the lipophilic xenobiotic molecules are converted into more hydrophilic 
metabolites so that they can be excreted from the body in phase III.  
 17
Phase I reactions include oxidation, reduction, hydrolysis, and some other reactions 
(146). Cytochrome P450 (CYP) are the major heme-dependent monooxygenases that 
catalyze phase I reactions (118). The CYP3A subfamily catalyzes oxidation of diverse 
xenobiotics in liver and intestine. Many CYP3A substrates also induce their expression 
(147) and evidence linking PXR to the regulation of CYP3A gene expression, includes 
the following observations: 1) PXR and CYP3A are both highly expressed in the liver 
and small intestine (92,95); and 2) almost all chemicals that induce CYP3A genes can 
activate PXR (88). The species-specific PXR agonists also induce species-specific 
CYP3A expression, as discussed above in 1.2.2 (94,125,148). 3) upon agonist activation, 
PXR forms a heterodimer with RXR and binds to xenobiotic response elements in 
CYP3A promoters (88-90,149). These elements contain two copies of consensus nuclear 
receptor binding motifs (AG(G/T)TCA), in the form of DR-3 (direct repeat of motif with 
a 3 bp spacer) in the CYP3A5, CYP3A7, CYP3A1, and CYP3A2 promoters and 
CYP3A4 enhancer (89,90). Other elements include an ER-6 (everted repeat with 6 bp 
spacer) in the CYP3A4 promoter (149), a DR-4 and ER8 in other target genes such as 
CYP2B, CYP2C, and MDR1, MRP2 (89,150-152). 4) The major PXR regulated CYP3A 
gene in mice, CYP3A11, was not induced by PCN or dexamethasone in the PXR-null 
mice. The PXR-null mice were sensitive to xenobiotics that are metabolized by 
CYP3A11 (122,131). 
In phase I reactions, PXR also regulates other phase I monooxygenases, including 
CYP2B6, CYP2B9, CYP2C8, CYP2C9, and CYP2C19 (140,151,153,154). Other phase 
I drug metabolism genes regulated by PXR include carboxylesterases, dehydrogenases, 
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and some enzymes involved in heme production and the P450 reaction cycle (155,156). 
Phase II genes regulated by PXR include sulfotransferases, UDP-
glucoronosyltransferases, glutathione-S-transferases, and carboxylesterases (157-162). 
PXR also regulates phase III drug efflux genes such as multidrug resistance 1 (MDR1), 
multidrug resistance associated protein 1, 2, 3 (MRP1A/B, MRP2, and MRP3), and 
breast cancer resistance protein (BCRP/ABCG2) (127,131,140,150,152,163). PXR not 
only plays an important role in drug metabolism but also regulates genes in bile acid 
synthesis, transport, and metabolism, including cholesterol 7α-hydroxylase and Na+-
dependent organic anion transporting polypeptide 2 (Oatp2) (131). Table 1.5 lists major 
PXR regulated genes in human and mouse. 
1.2.4 PXR coregulators 
Upon ligand binding, PXR forms a heterodimer with RXR and subsequently binds 
to response elements in target gene regulatory regions to activate gene transcription. 
Elaborate gene regulation is mediated by recruitment of coregulators and it has been 
suggested that binding of ligand changes the conformation of the AF-2 region in the C-
terminal end of LBD and creates a coactivator-binding cleft (112). 
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Table 1.5. PXR regulated genes in human and mouse. 
Gene Function Response elements 
CYP3A4 
CYP3A7 
DR-3, DR-4, ER-6 
ER-6 
mCYP3A11, mCYP3A13 
rCYP3A2 
rCYP3A23 
Phase I metabolism 
 
DR-3 
DR-4 
CYP2C9, CYP2C8, CYP2C19  DR-4 
CYP1B1, CYP2B6, rCYP2B1/2, mCYP2B10  DR-4 
CYP1A1, CYP1A2   
CYP2A6 
ALDH1A1, mALDH1A7, 1A1 
  
GSTA2, mGSTA1 Phase II metabolism  
UGT1A1, UGT1A3, UGT1A4, mUGT1a1   
SULT1A1, SULT2A1   
MDR1,  
mMRP1A/B,  
mMRP2,  
mMRP3, mOATP2 
rOATP2  
BCRP, BSEP, slc21a5 
Phase III transporter DR-4 
 
ER-8 
 
DR-3 
ALAS1, mALAS1 
mPAPS synthase 
mPor 
Essential accessory proteins 
 
 
cholesterol 7α-hydroxylase Bile acid metabolism  
CYP7A1, CYP8B1 Bile synthesis  
CYP24 Vitamin D hydroxylation  
m, mouse; r, rat; the others, human. (164) 
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Several coregulators interact with PXR and the p160 family member SRC-1 
(steroid receptor coactivator 1) was first PXR coactivator identified that binds PXR 
ligand-dependently, using the LXXLL repeats (90,165). Other coactivators that interact 
with PXR include glucocorticoid receptor-interacting protein 1 (GRIP1/SRC-2), SRC-3, 
peroxisome proliferator activated receptor binding protein (PBP), receptor interacting 
protein 140 (RIP140), peroxisome proliferators-activated receptor γ coactivator (PGC-1), 
and suppressor for Gal 1 (SUG-1) (94,100,120,129,166,167). Corepressors also interact 
with PXR and these include nuclear receptor corepressor (NCoR) (100,168). The 
interaction between silencing mediator of retinoid thyroid receptor (SMRT) and PXR is 
disrupted upon agonist treatment (169) and the small heterodimer partner (SHP) also 
interacts with PXR to repress its transcriptional activity (170).  
Other proteins are recruited through the coactivators to enhance PXR-dependent 
transcription and these include the transcriptional coregulator p300. Like SRC-1, p300 
exhibits histone acetyltransferase activity in remodeling chromatin and enhancing target 
gene transcription (171-174). SRC-1 also recruits coactivator-associated arginine 
methyltransferase 1 (CARM1) and synergistically enhances target gene transcription 
(49).  
Interactions between PXR and coregulators can also be influenced by post-
translational modifications. Phosphorylation of mouse PXR by protein kinase A 
enhances interactions between PXR and SRC1 or PBP (175). However, mouse PXR is 
phosphorylated by protein kinase C and this decreased interactions between PXR and 
SRC1 (100). RXRα phosphorylation at serine 32 also inhibits PXR activity (176).  
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1.2.5 PXR interplays with other NRs 
CAR 
The nuclear receptor not closely related to PXR is constitutive androstane receptor 
(CAR). These receptors functionally overlap in ligand binding and gene activation. 
Originally, it was shown that PXR regulates CYP3A and CAR regulates CYP2B genes 
(90,123,177,178). However, new studies showed that both CAR and PXR are activated 
by rifampicin and phenobarbital (130). PXR activates CYP2B genes through binding to 
the phenobarbital response element (PBPE), which is the CAR recognition site 
(122,151). CAR can also activate CYP3A genes through binding to DR-3 and ER-6 
elements which are PXR/RXR binding sites (179-181). Other genes coregulated by PXR 
and CAR include CYP2C genes, glutathione-S-transferases, sulfotransferases, UDP-
glucoronosyltrnasferases and MRP2 (152,153,182). CAR and PXR exhibit differences in 
specific genes they activate. For example, PXR regulates Aldh1a1, Aldh1a7, CYP3A11, 
GSTA1, GSTM2, and MDR1B which are not regulated by CAR. CAR regulates 
CYP1A1, CYP2A4, and SULTN which are not regulated by PXR (182).  
FXR 
Toxic secondary bile acids, such as lithocholic acid (LCA), are ligands for both 
PXR and FXR (129,131). LCA activates PXR and induces CYP3A and Oatp2, and 
represses CYP7A1 (183,184). Bile acids-dependent activation of FXR induces small 
heterodimer partner SHP an inhibitor of liver receptor homolog-1 (LRH-1), which is 
responsible for induction of CYP7A1 (185). SHP can inhibit PXR and PXR can also 
regulate SHP (170,186). FXR also regulates CYP3A4 through binding to the response 
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elements in the CYP3A4 promoter (123). FXR binding elements also exist in the PXR 
promoter and PXR is directly regulated by FXR (187).  
VDR 
    Vitamin D plays a role in the maintenance of bone density by activating VDR 
and activation of VDR target gene CYP24 regulates vitamin D levels (188-190). Many 
PXR agonists can cause osteomalacia. CYP3A4 was recently shown to metabolize 
vitamin D in human liver and small intestine, whereas CYP24 expression is very low 
(190). Further evidence showed that PXR inhibits VDR-mediated CYP24 expression 
(191). VDR also activates CYP3A4 upon ligand treatment and SULT2A1 is another 
gene regulated by both PXR and VDR, and by CAR (192). 
 
1.3 CHROMATIN AND GENE REGULATION 
As described above, nuclear receptors (NRs) are ligand-dependent, DNA-binding 
transcription factors. In eukaryotic organisms, DNA is compacted in chromatin, in the 
nucleus and the chromatin remodeling is very critical for the transcriptional machinery 
to access target gene promoters. Many enzymes that remodel nucleosomes or modify 
histones are nuclear receptor coactivators.  
1.3.1 Chromatin structure 
DNA was considered as the storage facility for all genetic information; however, 
after completion of the human genome project, there were several unsolved mysteries 
that cannot be simply explained by DNA information. For example, the number of 
protein coding genes in human is 35,000 only, twice the number of Drosophila genes. It 
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is also known that the genetic profiles of human and mouse share 99% homology. In 
addition, the whole organism is developed from a single zygote. How does it divide and 
differentiate into so many cell types? Different cells express different genes and develop 
different morphology and functions yet all somatic cells share identical genome 
sequences. 
Epigenetics is an emerging field of science that is beginning to provide some 
answers to these questions. In their review, David Allis and Emily Bernstein described 
epigenetics broadly as “a phenomenon that changes the final outcome of a locus or 
chromosome without changing the underlying DNA sequence”, and more specifically as 
“the study of any potentially stable and, ideally, heritable change in gene expression or 
cellular phenotype that occurs without changes in Watson-Crick base-pairing of DNA” 
(193). DNA and histone modifications can influence the chromatin structure and thus 
influence gene expression, which provides an important molecular mechanism for 
epigenetic phenomena.  
In eukaryotic cells, DNA is packaged by histones and nonhistone chromosomal 
proteins (such as HMG proteins) into a condensed structure called chromatin. By this 
packaging, a 2-meter-long strand of DNA is compacted in the tiny nucleus with a 
diameter of around five micrometers. The primary package structure is the basic unit 
called the nucleosome, as shown in Fig. 1.2, with a 147 base pair core DNA wrapping an 
octamer of core histones for two rounds. The octamer core histone is composed of a 
heterotetramer of histones H3 and H4, and two heterodimers, H2A and H2B. The 
nucleosomes are connected by a 10-60 bp linker DNA bound with linker histone H1 and 
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a nonhistone HMG protein (194-197). In a higher order, nucleosomes are packaged into 
30nm-wide chromatin and further condensed into 100 nm-wide chromosomes during 
mitosis. This highly packaged chromatin structure represents an obstacle for gene 
transcription by restricting transcription factor binding (195). To activate genes, DNA 
must be released from the highly compacted nucleosome structure to allow recruitment 
of RNA polymerase II transcriptional apparatus to the regulatory regions and exert 
transcription initiation and elongation (198,199). In general, there are two processes that 
can execute this function. ATP-dependent chromatin remodeling by SWI/SNF or NURF 
can change regional chromatin structure and expose the DNA to facilitate activation 
(200,201). The other process is histone modification. 
1.3.2 Histone modifications 
The C-terminal major domains of core histones form globular structures and 
interact with each other (196,202). The highly dynamic N-terminal tail of each histone 
protein extends from the surface and interacts with DNA, other nucleosomes, or 
cofactors (203). A large number of amino acids in this domain are dynamically modified 
and play an important role in gene regulation, signal transduction, chromosome 
modeling, DNA repair, DNA replication, and other processes (204-206). Mistakes in 
histone modifications may be important in human diseases, such as cancer (207).  
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Figure 1.2. Structure of nucleosome. 147 bp core DNA wraps a core histone octamer for two rounds. 10-
60 bp linker DNA binds with linker histone H1. The amino-terminal tails of each histone protrude, 
containing specific sites for post-translational modifications, which are marked by their sequential 
numbers. 
 
 
The histone modifications include phosphorylation (208), acetylation (209), 
methylation (210), ubiquitylation (211), sumoylation (212), ADP ribosylation (213), 
deimination (214,215), and proline isomerization (216). Those modifications on histones 
affect the chromatin structure or provide a binding site for coregulators (205). Based on 
what type of modification takes place and which amino acid is modified, distinct cellular 
processes are associated. Also, several different enzymes are responsible for 
modifications on specific amino acids. A list of histone modification enzymes is 
presented in Table 1. 6. 
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1.3.2.1 Histone acetylation 
Histone acetylation has been correlated with active transcription in vivo for over 35 
years (217). Histone acetylation homeostasis is controlled by two types of enzymes, 
histone acetyltransferases (HATs) and histone deacetylases (HDACs) (218-220). 
Approximate 30 known HATs are divided to two types, type A-HATs which acetylate 
histone to regulate chromatin remodeling and gene transcription, and type B-HATs 
which acetylate histone in the cytoplasm before histone incorporation into newly 
replicated chromatin (221-223). There are 18 mammalian HDACs, divided to three 
classes. Class I HDACs include HDAC-1, -2, -3, -8, and -11. Class II include HDAC-4, -
5, -6, -7, -9, and -10. Class III HDACs are SIRT (silent mating type information 
regulation 2 homolog) proteins (224). 
1.3.2.2 Histone methylation 
Histone methylation takes place on lysine and arginine. Lysines 4, 9, 27, and 36 of 
histone H3 and lysine 20 of H4 are targets for lysine methyltransferases. These lysine 
methyltransferases share a conserved 130 amino acid SET-domain (205). Arginine 
methyltransferases are discussed in detail later. H3K79 is a residue in the core domain 
that can be methylated in yeast for gene silencing (225,226). Histone methylation has 
long been considered irreversible. However, recent studies provided evidence of histone 
demethylase activity with several proteins, including LSD1, and JMJD2 subfamily 
members (227-229). 
 
 
 27
Table 1.6. Histone modification enzymes 
Enzymes Residues modified Enzymes Residues modified 
Acetyltransferase Lysine methyltransferase 
Pr-SET 7/8 
SUV420H1-2 
SpSet9 
EZH2 
RIZ1 
H4K20 
H4K20 
H4K20 
H3K27 
H3K9 
Lysine Demethylase 
HAT1 
CBP/P300 
 
 
PCAF/GCN5 
TIP60 
 
HB01(ScESA1, 
SpMST1) 
ScSAS3 
ScSAS2(SpMST2) 
ScRTT109 
H4 (K5, K12) 
H3 (K14, K18) H4 (K5, 
K8) H2A (K5) H2B (K12, 
K15) 
H3 (K9, K14, K18) 
H4 (K5, K8, K12, K16) 
H3K14 
H4 (K5, K8, K12) 
 
H3 (K14, K23) 
H4K16 
H3K56 
Deacetylase 
SirT2(ScSir2) H4K16 
Lysine methyltransferase 
LSD1/BHC110 
JHDM1a 
JHDM1b 
JHDM2a 
JHDM2b 
JMJD2A/JHDM3A 
JMJD2B 
JMJD2C/GASC1 
JMJD2D 
H3K4 
H3K36 
H3K36 
H3K9 
H3K9 
H3K9, H3K36 
H3K9 
H3K9, H3K36 
H3K9 
Arginine Methyltransferase 
CARM1 
PRMT1 
PRMT5 
H3 (R2, R17, R26) 
H4R3, H2A R3 
H4R3, H3R8 
Serine/Thrionine Kinase 
Haspin 
MSK1, MSK2 
CKII 
Mst1 
H3T3 
H3S28 
H4S1 
H2BS14 
Ubiquitylase 
Bim1/Ring1A 
RNF20/RNF40 
H2AK119 
H2BK120 
Proline isomerase 
SUV39H1, SUV39H2 
G9a 
ESET/SETDB1 
EuHMTase/GLP 
CLL8 
SpClr4 
MLL1-5 
SET1A, SET1B 
ASH1 
Sc/Sp SET1 
SET2 (Sc/Sp SET2) 
NSD1 
SYMD2 
DOT1 
Sc/Sp DOT1 
H3K9 
H3K9 
H3K9 
H3K9 
H3K9 
H3K9 
H3K4 
H3K4 
H3K4 
H3K4 
H3K36 
H3K36 
H3K36 
H3K79 
H4K20 ScFPR4 H3P30, H3P38 
(230) 
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Interplay between different modifications is complex and provide mechanisms for 
the functions of histone modifications. A number of proteins that recognize specific 
modification and also exhibit enzymatic activity have been identified. BPTF recognizes 
H3K4me3 and recruits the NURF chromatin-remodeling complex to activate 
downstream gene (231). JMJD2A and CHD1 proteins bind to H3K4me mark to perform 
histone lysine demethylase and ATPase activities, respectively (232-234). Polycomb 
protein PC2 recognizes H3K27me and recruits ubiquitin ligase for H2A. Different 
modifications cannot occur on the same lysine. Recent evidence has also shown that one 
site-specific modification can influence adjacent modifications. For example, 
phosphorylation of H3S10 reduces binding of HP1 to H3K9me (235). Isomerization of 
H3P38 also reduces methylation of H3K36 by Set2 (216). H3S10 phosphorylation 
facilitates GCN5 acetyltransferase recognition of H3 (236). Ubiquitinylation of H2B is 
required for methylation of H3K4me3 (237,238).    
1.3.3 Histone modifications and gene transcription  
Histone modifications function to establish a global chromatin environment, 
euchromatin or heterochromatin, and to facilitate DNA-based functions which include 
transcription, DNA repair, and DNA replication.   
Silent heterochromatin and active euchromatin exhibit different histone 
modifications. Heterochromatin, which is important during separation of chromosomes, 
has low level of total acetylation and high level of methylation on H3K9, H3K27, and 
H4K20. H3K9 methylation is recognized by heterochromatin associated protein HP1 and 
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is further stabilized by HP1 to maintain the heterochromatin state (239). 
Hyperphosphorylation is also linked to condensed chromatin (220).  
In a euchromatin environment, a transcription factor is recruited to the promoter 
upon stimulation, and promotes modifications which result in gene activation or 
repression. Histone modifications in the promoter or on the coding region may exhibit 
opposite functions (240). 
1.3.3.1 Acetylation 
Acetylation is primarily associated with gene activation. Acetyltransferases, such as 
CBP/p300, GCN5, have been identified as coactivators (48,55). Most HATs modify 
multiple lysines on the N-terminal tail of histones (48). Only lysine 56 on H3 is a lysine 
within the core domain that can be acetylated (241-243). The hypothesis that histone 
acetylation changes the surface charges and destabilize the histone-DNA interaction is 
supported by observation that acetylated histones are easier to displace from DNA (244-
246). Another mechanism is that histone modifications including acetylation can be 
recognized by other proteins and result in gene activation or repression, depending on 
those proteins that recognize the modification. In contrast, histone deacetylases 
(HDACs) correlate with gene expression. Most HDACs don’t have much preference for 
specific sites. However, H4K16 acetylation is a special case that it is deacetylated by 
yeast sir2 and its human analogues (247). Different from other acetylation, the function 
of H4K16 acetylation is to inhibit the formation of 30nm chromatin fibers (248).  
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1.3.3.2 Methylation 
Histone methylation catalyzed by histone methyltransferases (HMTs), which 
contain a conserved SET domain (205) can occur on lysine or arginine (249,250). 
Activation associated H3K4 methylation is mediated by the SET1 complex in yeast and 
it distributes across the whole ORF (211). The MLL/WRD5 complex recognizes 
dimethylated H3K4 and generates trimethylation on this residue in humans (251). In 
yeast, H3K4me3 primarily localizes to the 5’ end and is associated with RNA Pol II 
(252). Several proteins with chromating remodeling or histone modification activities 
also contain domains that recognize this methylation, including chromatin-remodeling 
factor NURF and Chd1, mouse SIN3/HDAC, and human Tip60. H3K36 methylation 
mediated by Set2 is also associated with elongation. Both di- and trimethylation of this 
lysine mainly localize to 3’ ORF and associates with elongation form of Pol II. EAF3 
protein recognizes this methylation and brings the Rpd3S deacetylase complex to the 
ORF. Acetylation in this region is removed to prevent inappropriate internal 
transcription (253-255).   
Methylation on H3K9 in the promoter facilitates binding of the heterochromatin 
protein 1 (HP1) to chromatin. HP1 recruits other factors including SUV39H1 which 
methylate H3K9 and HDACs leading to heterochromatic gene silencing (249,256). HP1 
family members also interact with DNM1 and trigger DNM1 to methylate DNA, which 
is another repression marker (257). Methylation on H3K27 and H4K20 has been 
implicated in heterochromatin formation. 
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Histone arginine methylation can be associated with gene activation or repression. 
Two members of protein arginine methyltransferases (PRMTs), PRMT1 and 
PRMT4/CARM1, were discovered as nuclear receptor coactivators (50,63). CARM1 
specifically methylates arginines 2, 17, and 26 of H3, while PRMT1 specifically 
methylates arginine 3 of H4 (258). In the estrogen-regulated pS2 promoter, arginine 
methylation was observed to be cyclic during activation (259). Proteins that recognize or 
remove arginine methylation have not been identified. Deimination by PADI4 converts 
arginine to citrulline and prevent arginine methylation (214,215). Mono- but not 
dimethylated arginine can also be converted to citrulline (215). The reverse process, 
converting citrilline to arginine has not been reported. JMJD6, a member of the lysine 
demethylase family, was reported to demethylate H3R2 and H4R3 (260).  
1.3.3.3 Phosphorylation 
Histone phosphorylation is involved in chromosome condensation, gene activation, 
response to DNA damage, and induction of apoptosis (261). Phosphorylation of serine 
10 H3 (H3S10) occurs during mitosis and alters gene regulation (262). Phosphorylation 
of H3 by ribosomal S6 kinase 2 (RSK-2) and MAP and stress-activated kinase 1 (MSK-
1) is responsible for this phosphorylation and intracellular signal transduction (263,264). 
Phosphorylation of linker histone H1 by cyclin-dependent kinase 2 (cdk2) causes its 
dissociation from chromatin and influence on gene transcription (265).  
These different histone modifications interact with each other. The active or 
repressive transcriptional stage may be dictated by a series of modifications. For 
example, CARM1 and p300 show synergism in estrogen receptor-mediated gene 
 32
regulation (49). Methylation of H4R3 by PRMT1 can increase acetylation of H4K8 and 
H4K12 by p300, although preacetylation of H4 will reduce the H4R3 methylation by 
PRMT1 (50). SET9 methylation of H3 stimulates the subsequent acetylation of H3 and 
H4 by p300, while SUV39H1 methylation of H3 inhibits the same acetylation (266). 
 
1.4 PROTEIN ARGINING METHYLTRANSFERASES (PRMTs) 
1.4.1 Protein arginine methyltransferase overview 
Protein arginine methyltransferases (PRMTs) are members of the methyltransferase 
family that transfer a methyl group from S-adenosylmethionine (SAM or AdoMet) to the 
guanidine group of protein arginine residues (267). PRMTs have been discovered in 
many species, including fungi, plants, invertebrates, and vertebrate animals (267-270). 
Nine mammalian PRMTs have been identified, PRMT1-9, while only one was observed 
in yeast, Hmt1/Rmt1 (271). PRMTs are classified as type I or type II. PRMT1, -3, -4, -6, 
and -8 are type I enzymes that form monomethylarginine (MMA) or asymmetric 
dimethylarginine (ADMA). PRMT5 is a type II PRMT, which produces MMA and 
symmetric dimethylarginine (SDMA) (271,272). The other three, PRMT2, PRMT7, and 
PRMT9 were discovered by homology and their activities have not yet been determined 
(273).   
Proteins with glycine and arginine rich (GAR) motifs are known substrates of 
PRMTs. PRMT1, -3, and -6 usually recognize the GAR motif. PRMT1 was shown to 
recognize Arg-Gly-Gly repeats (274). CARM1/PRMT4 does not recognize the GAR 
motif but methylates other specific substrates (275). PRMT5 and PRMT7 recognize and 
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methylate isolated arginines or arginines in GAR motifs (276). A list of known PRMT 
substrates is given in Table 1.6. 
 
 
Table 1.7. Partial listing of histone and non-histone substrates for PRMTs  
PRMT Type Histone substrate Nonhistone substrate 
PRMT1 
 
Type I Histone H4, H2A Fibrillarin, Nucleolin, Sam68, 
FGF-2, STAT1, STAT3, EWS, 
SAF-A, NIP45, Mre11, hnRNP 
A1, hnRNP A2, hnRNP R, 
hnRNP K, SPT5, CIRP, ILF3, 
TLS/FUS, RNA helicase A, 
TAFII68, RBP58, ZF5, 
p137GP1, SAMT1 
PRMT3 Type I  rpS2, PABPN1 
PRMT4/ 
CARM1 
Type I Histone H3 PABP1, p300/CBP, HuR, 
TARPP, Sm B/B’ 
PRMT5 
 
Type II Histone H4, H2A, H3 MBP, Sm D1, Sm D3, Sm B/B’, 
coilin, LSm4, SPT5 
PRMT6 Type I  PRMT6, Fibrillarin, HIV tat 
PRMT7 Type II  Fibrillarin 
(271) 
 
 
Methylation of an arginine residue can alter the interaction between the modified 
protein and other proteins or molecules, resulting in altered functions of the methylated 
proteins (205). The outcome of protein methylation by PRMTs can result in alteration of 
transcriptional regulation, signal transduction pathways, nuclear-cytoplasmic transport, 
and posttranscriptional modification of gene expression (271). 
1.4.2 PRMTs function as coactivators 
Several PRMTs are coactivators of nuclear receptors. They can methylate receptors, 
coregulators, transcriptional factors, and histones to regulate transcription. CARM1 
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methylates the N-terminus of histone H3 and was the first PRMT identified as a 
coactivator that is recruited through p160 coactivators to nuclear receptors bound to 
promoter regions of specific genes (277). PRMT1, that methylates histone H4 and was 
also identified as a nuclear receptor coactivator that binds to p160 (278). The 
associations with p160 are required for both CARM1 and PRMT1 coactivator functions 
(44,49,279). Methylation of H3R17 and H3R26 by CARM1 and methylation of H4R3 
by PRMT1 are also transcriptionally active markers (50,205). The methyltransferase 
activity of PRMT2 has not been described and this methyltransferase is also a 
coactivator for AR and ERα (280) and inhibits IκB-α export from nucleus and thus 
inhibit NF-κB transcription (281). PRMTs are also identified as coactivators of p53, 
YY1, PPARγ, RUNX1, and E2F1 (282,283).  
It has also been suggested that arginine methylation interacts with other protein 
modifications, thereby facilitating transcriptional activation. Synergistic cooperations 
between CARM1 and PRMT1 (279), and between CARM1, CBP/p300 and pCAF have 
been reported (284). PRMT1, CARM1 and p300/CBP were recruited through p160 
(279). PRMT1 methylation of histone H4 was detected to increase the subsequent 
acetylation of H4 by p300 (50) and acetylation of nucleosomes in p53-dependent 
transcription (285). An in vivo study showed that PRMT1 methylation of H4 is essential 
for subsequent histone modifications (286). Preacetylated histone H4 by p300 is 
inhibitory to methylation by PRMT1 (50); however, preacetylated H3 by p300 enhances 
methylation by CARM1 (287). 
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Besides interplay between histone modifications, CARM1 also interacts with ATP-
dependent chromatin remodeling enzymes. CARM1 forms a complex with SWI/SNF 
factors and functions in many ways (288). First, the interaction between CARM1 and 
Brg1 increases Brg1 ATPase activity and changes CARM1 preference for free histone 
H3 to nucleasomal H3 (67). Second, a nuclear receptor coactivator, protein Flightless I, 
binds CARM1, Brg1, and the other SWI/SNF component BAF53 (289), which form a 
connection between histone modification and ATP-dependent chromatin remodeling. 
PRMTs also methylate nonhistone proteins to activate transcription. CBP/p300 are 
activators for many transcription factors, including nuclear receptors, cAMP response 
element binding protein (CREB), signal transducer and activator of transcription 1 
(STAT1), and activator protein-1 (290). Mutations of arginine residues reduced the 
coactivator function of CBP (49,284), indicating that methylation may be required for its 
coactivator functions. STAT1 methylation by PRMT1 at arginine 31 prevents binding of 
the PLAS1 inhibitor and promotes its activation (291). Receptor interacting protein 140 
(RIP140), a nuclear receptor corepressor, is methylated by PRMT1 to inhibit its 
repressive activity (292). Some small nuclear ribonucleoprotein particles (snRNPs, like 
SmD1 and SmD3), some heterogeneous nuclear ribonucleoproteins (hnRNPs), HNF4, a 
transcriptional factor, and HuR, an mRNA-stabilizing protein must be methylated for 
full function (68,275,293). 
1.4.3 PRMTs function as corepressors 
PRMT5 is the first PRMT identified as a corepressor for several transcription 
factors, including E2F1, Brg1, hBRM, Blimp1, and Snail (294-297). PRMT5 was known 
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to cause symmetrical dimethylation of H3R8 and H4R3 (298). However, its repression 
mechanism is not clear. PRMT6 is responsible for H3R2 methylation, which prevents 
MLL1 and WDR5 from methylating H3K4. In this way, it repress transcription by 
blocking the active H3K4 methylation mark (299-301). PRMT7 was described critical 
for DNA methylation of the imprint control region (302).  
PRMT1 and CARM1 also play a role in repression; for example, SPT5 is a 
transcriptional elongation factor that can be methylated by PRMT1 and PRMT5 to 
abolish its binding with RNA pol II, and therefore inhibit its elongation activity (303). 
Although CARM1 performs synergistic activation with CBP/p300; CARM1 methylation 
of CBP/p300 prevents its interaction with transcription factors, resulting in inhibition of 
CBP/p300 coactivator functions (67,304). 
The high mobility group protein (HMG) is a family of proteins which binds to 
linker DNA between nucleosomes to stabilize the chromatin structure (305). AT hook is 
a motif in HMG proteins that can be methylated. It has been suggested that methylation 
of AT hooks may be related to protein-DNA or protein-protein interactions (306).  
1.4.4 Regulation of PRMTs 
The enzyme activities of PRMTs can be regulated by their binding proteins, BTG1 
and BTG2 (307). A BTG1-binding protein, hCAF1 exhibits substrate-dependent 
regulation of PRMT1 (308). DAL-1 can inhibit PRMT3 activity (309). Within NUMAC 
(nucleosomal methylation activator complex), CARM1 can methylate nucleosomal H3, 
while it only methylates free H3 in vitro (288). Binding to BRG and BRM enhances 
PRMT5 activity, and binding to CTCFL enhances PRMT7 activity (298,302). 
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Modification of PRMTs can also regulate their activity. CARM1 phosphorylation 
prevents its homodimerization and inhibit its enzyme activity (310). Automethylation of 
PRMT1, -4, -6, and -8 were reported without clear functional consequences (311). 
Other modification marks usually prevent the adjacent arginine to be methylated. 
H3K9 acetylation inhibits H3R8 methylation (298). H3R8 methylation also inhibits 
H3K9 methylation (312). H3K4 trimethylation but not mono- or dimethylaiton can 
inhibit H3R2 methylation by PRMT6 (299,301). H3R2 also inhibits H3K4 methylation 
(300). 
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CHAPTER II 
EPIGENETIC REGULATION OF TRANSCRIPTIONAL ACTIVITY OF 
PREGNANE X RECEPTOR BY PROTEIN ARGININE 
METHYLTRANSFERASE 1 
 
2.1 OVERVIEW 
Pregnane X receptor (PXR) is an orphan nuclear receptor that regulates metabolism 
and disposition of various xenobiotics and endobiotics (313). These physiological 
functions of PXR are achieved through coordinating transcriptional regulation of Phase I 
and Phase II drug-metabolizing enzymes as well as the “Phase III” transporters (164). 
The structural flexibility in the ligand binding pocket enables PXR to function as a 
xenobiotic receptor through interacting with a wide range of structurally diverse 
compounds (114). Xeno- and endobiotics that activate PXR include a variety of 
prescription and nonprescription drugs, herbal medicines, environmental toxicants, and 
bile acids (314).  
Post-translational modifications on the N-termini of histones have been shown to 
play critical roles in gene regulation including the regulation of transcriptional activity 
by nuclear receptors. These modifications include phosphorylation, acetylation, 
methylation, and ubiquitination (230). It is believed that combination of  
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modifications of the chromatin-associated histone and non-histone proteins, and the  
interplay between these modifications create a marking system (“histone code”), which 
is part of the epigenetic mechanisms for gene regulation (205).  
The protein arginine methyltransferases (PRMTs) including PRMT1, PRMT2, and 
PRMT4 (CARM1) were shown to be nuclear receptor coactivators (277,279,315,316). 
These enzymes regulate gene expression through methylating histone and non-histone 
proteins, and the methylation marks are important for the nuclear/steroid hormone 
receptor-mediated transcriptional activity. PRMT1 is a major arginine methyltransferase 
which methylates arginine 3 of histone H4 and H2A. Recent evidence suggests that 
histone modification by PRMT1 sets the stage for subsequent histone modifications 
(286), and there is an intricate interplay between H4R3 methylation and other histone 
modifications. For example, arginine methylation (H4R3) by PRMT1 facilitates H4 
acetylation but H4 acetylation inhibits methylation of H4R3 (50). These observations 
suggest that histone modifications during transcription proceed in a unidirectional 
sequence and in order to complete a transcription cycle, methylated H4R3 has to be 
demethylated, followed by acetylation and then deacetylation or replacement (317). 
Understanding the role of these histone modification enzymes in nuclear receptor-
regulated gene expression will help us understand the epigenetic mechanism of gene 
regulation and provide important basis for drug/therapeutic designs to effectively 
intervene in pathological processes such as tumorigenesis and inflammatory responses.  
In this study, we identified PRMT1 to be a major HMT associated with PXR, and 
we demonstrate that PRMT1 is a required histone methyltransferase for PXR 
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transcriptional activity. PRMT1 regulates PXR transcriptional activity by direct 
association with PXR in a ligand-dependent manner, and the PXR agonist rifampicin 
caused recruitment of PRMT1 to the regulatory region of PXR target gene CYP3A4. 
Knockdown of PRMT1 through siRNA or gene deletion inhibited PXR-dependent 
transcriptional activity. Furthermore, we found that PXR plays a critical role in 
regulating PRMT1 cellular compartmentalization and substrate preference. 
 
2.2 MATERIALS AND METHODS 
2.2.1 Materials 
DMSO, rifampicin, PCN, anti-FLAG M2 antibody, and anti-FLAG M2-agarose 
affinity beads were from Sigma. Core histones were from Roche (Indianapolis, IN). S-
Adenosyl-L-[methyl-3H]-methionine ([3H]SAM) and [35S]-methionine were from 
PerkinElmer (Waltham, MA). Recombinant histone H4, acetylated H4 N-terminal 
peptides, recombinant PRMT1, as well as anti-acetyl-(pan) H4, anti-H4 (Me2) R3, and 
anti-PRMT1 antibodies were purchased from Upstate (Millipore, Billerica, MA). Goat 
and mouse anti-PXR antibodies, and isotype IgGs were from Santa Cruz Biotechnology 
(Santa Cruz, CA). Nitrocellulose and polyvinylidene difluoride membranes were from 
Bio-Rad. 
2.2.2 Cells 
HepG2 and CV-1 cells were cultured in Dulbecco’s modified Eagle’s medium 
(HyClone, Logan, UT) supplemented with 10% fetal bovine serum (Sigma) and 1x 
antibiotic and antimycotic (Invitrogen, Carlsbad, CA). PXR-HepG2 and PXR-HT29 
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stable transfectants were created as described in (318). Wild-type and PRMT1-null ES 
cells were obtained from Mark Bedford (MD Anderson, Houston, TX) and cultured 
according to (319). 
2.2.3 Plasmids 
Plasmids expressing GST-fused PXR fragments have been created in our 
laboratory. DNA sequences coding different PXR fragments were PCR-amplified and 
subcloned into pGEX-5X-3 expression vector (Amersham Biosciences). pACT, pBIND, 
and pG5-luc were purchased from Promega (Madison, WI) for the mammalian two-
hybrid assay. pBIND-PXR (Gal4-PXR) and pACT-PRMT1 (VP16-PRMT1) were 
constructed by inserting PCR-amplified human PXR DNA sequence into pBIND vector 
and PCR-amplified PRMT1 DNA sequence into pACT vector following the 
manufacturer’s recommendation (Promega). 
2.2.4 Co-immunoprecipitation (co-IP) 
PXR-HepG2 cells were washed with PBS and homogenized in the Co-IP lysis 
buffer (20 mM Hepes, pH 7.4, 125 mM NaCl, 1% Triton X-100, 10 mM EGTA, 2 mM 
Na3VO4, 50 mM NaF, 20 mM ZnCl2, 10 mM sodium pyrophosphate, 1 mM 
dithiothreitol, and 1 mM phenylmethylsulfonyl fluoride). Complete protease inhibitor 
mixture (Sigma) was added before use. Mouse liver tissues were homogenized in the 
same (above) lysis buffer. After centrifugation (12,000 x g in a microcentrifuge at 4 °C 
for 15 min), supernatant fractions were collected and incubated with antibodies and 
GammaBind Plus-Sepharose beads (Amersham Biosciences) for 2 h at 4 °C on a rotary 
shaker. Corresponding isotype IgG was used as a negative control. The beads were 
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washed three times, and the precipitated protein complexes were analyzed with HMT 
assay or Western blot. 
2.2.5 Western Blot  
Proteins were analyzed by SDS-PAGE and then transferred to a nitrocellulose 
membrane. After over 4 h of blocking in 5% milk with TBST buffer (20 mM Tris-HCL, 
pH 7.6, 137mM NaCl, 0.5% Tween 20), the blot was incubated with appropriate primary 
antibodies at 37 °C overnight. After washing with TBST buffer for 30 min, the 
membrane was then subjected to 1:2000 corresponding alkaline phosphatase-conjugated 
secondary antibodies for 2 h. After another wash with TBST for 30 min, the membrane 
was exposed to Nitro Blue tetrazolium/BCIP as the substrate (Promega). 
2.2.6 Histone Methyltransferase Assay 
The PRMT1 (Upstate) HMT assay was based on the manufacturer’s 
recommendation. In brief, 2 μg of core histones, 2 μg of H4, or 0.4 μg of H4 N-terminal 
peptides were incubated with the immunoprecipitated HMT complexes or recombinant 
PRMT1 at 30 °C for 90 min, in 1xHMT buffer (50 mM Tris, pH 9.0, 1 mM 
phenylmethylsulfonyl fluoride, 0.5 mM dithiothreitol) with S-adenosyl-L-[methyl-
3H]methionine ([3H]SAM) as the methyl donor. The reaction mix was separated in 16% 
SDS-PAGE, and the separated proteins were transferred to the polyvinylidene difluoride 
membrane for autoradiography and staining with Ponceau BS red dye (Sigma).  
2.2.7 Peptide Sequencing Analysis 
The radioactive proteins identified by autoradiography were excised from the 
membrane for N-terminal sequencing by Edman degradation. The radioactivity in the 
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Edman degradation fractions corresponding to amino acid residues was determined by 
liquid scintillation counting. 
2.2.8 GST pull-down assay 
The GST pull-down assay was performed as described (52). Briefly, 
[35S]methionine-labeled fulllength PRMT1 protein was generated with a TNT-coupled 
Reticulocyte Lysate System (Promega) using the SP6 promoter-driven cDNA plasmid as 
the template. PCR-generated PXR cDNA fragments were inserted in-frame into pGEX-
5X-3 (Amersham Biosciences). The plasmids were expressed in Escherichia coli 
(BL21), and fusion polypeptides were purified with glutathione-Sepharose 4B beads 
(Amersham Biosciences) according to the manufacturer’s instruction. Twenty 
micrograms of each fusion polypeptide (estimated by comparison with bovine serum 
albumin in an SDS-PAGE gel with Coomassie Blue staining) was incubated with 20 μl 
of radiolabeled PRMT1 in a total volume of 200 μl of binding reaction buffer (20 mM 
Hepes pH 7.9, 1% Triton X-100, 20 Mm dithiothreitol, 0.5% bovine serum albumin, and 
100 mM KCl) for 3 h at 4 °C. After incubation, beads were washed three times with the 
same buffer without bovine serum albumin. The bound proteins were eluted by boiling 
in the SDS-PAGE sample buffer and resolved by 12% SDS-PAGE gel electrophoresis. 
The signals were detected by autoradiography. The input control was 2 μl of the 
radioactive PRMT1. 
2.2.9 Transient transfection and Luciferase assay 
Cells were seeded in 12-well plates. When growth reached 50% confluence, cells 
were transfected with plasmid DNA for 12 h using Lipofectamine (Invitrogen). The 
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transfected cells were treated with chemicals or vehicle for an additional 48 h. The 
luciferase assay was performed using a luciferase assay system kit, according to the 
manufacturer’s recommendation (Promega). 
2.2.10 Mammalian two hybrid assay 
The mammalian two-hybrid assay was performed using Checkmate Mammalian 
Two Hybrid System (Promega). CV-1 cells were seeded in 12-well plates and transient 
transfected with pBIND-PXR, pACT-PRMT1, and pG5-luc as shown in table 2.1. 12 h 
after transfection, cells were treated with rifampicin (10 μM, 48 h), and luciferase 
activity was determined with Polarstar optima luminometer (BMG Laboratory). 
 
 
Table 2.1. Experimental design for the mammalian two hybrid assays. 
Transfection pBIND pACT pG5-luc 
1 pGal4-PXR pACT pG5-luc 
2 pGal4-PXR pACT-PRMT1 full length pG5-luc 
3 pGal4-PXR pACT-PRMT1 SET domain pG5-luc 
4 pGal4-PXR pACT-PRMT1 N-terminus pG5-luc 
5 pGal4-PXR pACT-PRMT1 C-terminus pG5-luc 
According to the Checkmate Mammalian Two Hybrid System manual from Promega 
 
 
2.2.11 Small interference RNA 
Two small interfering RNA-expressing plasmids were constructed by cloning the 
sequences targeting PRMT1 at coding region sequences 756–773 (308) (siPRMT1–28) 
and 353–371(siPRMT1–11) into pSilencer 5.1 plasmids according to the manual 
(Ambion). The targeting plasmids were created by inserting 5’-
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GATCCGATCCACTGGTGGGAGAACTTCAAGAGAGTTCTCCCACCAGTGGATT
TTTTTGGAAAAGCT-3’ (siPRMT1–28), and 5’-
GATCCGCTCCATGTTTCATAACCGGTTCAAGAGACCGGTTATGAAACATGGA
GTTTTTTGGAAAAGCT-3’ (siPRMT1–11). The siRNA plasmids and the scramble 
siRNA control were co-transfected with PXR-directed reporter plasmid pGL3-3A4-Luc 
(318) into PXR-HepG2 cells. The transfected cells were treated with rifampicin (10 μM, 
48 h). Luciferase activity and PRMT1 protein expression were determined with 
luminometry and Western blotting, respectively. 
2.2.12 Chromatin Immunoprecipitation (ChIP) 
ChIP assay was performed according to the manufacturer’s protocol from Upstate, 
using the ChIP assay kit with modifications. Briefly, PXR-HepG2 cells were treated 
with rifampicin (10 μM, 2 h) and DMSO (vehicle control). Cells were cross-linked with 
1% formaldehyde for 15 min at room temperature, and then the reaction was stopped by 
incubating in glycine with a final concentration of 0.125 M for 5 min. Cells were washed 
three times with cold PBS and harvested by scraping with cell scraper. Then the cells 
were lysed in the SDS lysis buffer (1% SDS, 10 mMEDTA, and 50 mM Tris-HCl, pH 
8.1) on ice for 10 min. The samples were sonicated into DNA fragments of 0.2–1 kb 
(checked by agarose gel electrophoresis/ethidium bromide staining) and 
microcentrifuged at maximal speed for 10 min at 4 °C. The supernatant was precleared 
by rotating with 60 μl of salmon sperm DNA/protein-agarose slurry for 30 min at 4°C 
and then aliquoted after centrifugation. 20 μl was saved as input and 200 μl (equal to 
one-fifth the amount of cells from one 100% confluent 15-cm dish) was used for each 
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antibody. Each 200-μl supernatant was diluted with 800 μl of ChIP dilution buffer 
(0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8.1, and 167 
mM NaCl) and incubated with the specific antibody (1 μg/sample) at 4°C overnight. A 
mock precipitation without antibody was used as negative control. The next day, 60 μl of 
salmon sperm DNA/protein-agarose slurry was added to each sample and incubated at 
4°C for another 2–4 h. The beads were then washed for 3–5 min with 1 ml of each 
buffers listed: low salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM 
Tris-HCl, pH 8.1, 150 mM NaCl), high salt wash buffer (0.1% SDS, 1% Triton X-100, 
2mM EDTA, 20mM Tris-HCl, pH 8.1, 500 mM NaCl), and LiCl wash buffer (0.25 M 
LiCl, 1% IGEPAL-CA630, 1% deoxycholic acid (sodium salt), 1 mM EDTA, 10 mM 
Tris-HCl, pH 8.1). After all washes, pellets were suspended by vertex with 150 μl of 
freshly prepared elution buffer (0.1 M NaHCO3, 1% SDS) for 15 min, and then 
supernatant was collected. This elution progress was repeated once again, and in total 
300 μl elutes were collected. The one-tenth input was diluted with dilution buffer to a 
total volume of 300 μl. Elutes and diluted inputs were incubated in 0.3 M NaCl at 65°C 
for 4 h to reverse formaldehyde cross-linking. Then 10 μl of 0.5 M EDTA, 20 μl of 1 M 
Tris-HCl, pH 6.5, and 20 μg of proteinase K were added to the sample and incubated at 
45°C for 1 h. DNA was extracted with phenol/chloroform and then incubated with 10 μg 
of glycogen in 75% ethanol at -20°C overnight. After precipitation by centrifuging at 
12,000 x g for 30 min at 4°C, the recovered DNA pellets were dissolved in 30 μl of 
distilled water. The DNA target in the sample was determined by realtime quantitative 
PCR in triplicates with a 1-μl sample. Three independent experiments were performed. 
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Amplifications were performed in the 7500 Fast Real-Time PCR System (Applied 
Biosystems, Foster City, CA) with SYBR Green Master Mix (Applied Biosystems). The 
PCR primers used were: forward primer, 5’-GTCCCAATTAAAGGTCATAAAGC-3’ 
and reverse primer, 5’-CTTGAACCGACATGATTTCAAG-3’. 
2.2.13 Statistical analysis 
Statistical evaluations were conducted using two-tailed t test with triplicates for 
each treatment. A p value of less than 0.01 was considered to be statistically significant. 
Data are the means + S.D. of three independent results. 
2.2.14 Immunofluorescence microscopy 
Cells were seeded in chamber slides and kept in standard cell culture conditions. 
For microscopy, the cells were washed with PBS and then fixed with freshly prepared 
4% paraformaldehyde in PBS at 4°C for 10 min. After three washes, cells were 
permeabilized with 0.2% Triton X-100 in PBS for 10 min at room temperature. After 
another three washes, cells were blocked with 10% donkey serum in PBS/Tween (0.1% 
Tween20 in PBS) at room temperature for 3 h. Primary antibodies (mouse anti-PXR 
antibody with a dilution of 1:100, rabbit anti-PRMT1 antibody with a dilution of 1:500) 
in the blocking buffer were incubated with cells at 4°C overnight. The corresponding 
isotype IgG was used as negative control. After washing with PBS/Tween for three 
times, cells were incubated with anti-mouse red-fluorescent Alexa Fluor 568 or anti-
rabbit green-fluorescent Alexa Fluor 488 dyes (Invitrogen) in the PBS/Tween for 
another 2 h at room temperature. Cells were washed for three times and DAPI (Vector 
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Laboratory, Burlingame, CA) was added. The results were analyzed by fluorescence 
microscopy (Olympus IX71) equipped with Olympus DP70 digital camera. 
 
2.3 RESULTS 
2.3.1 Association of PRMT1 with PXR in HepG2 cells 
Histone methyltransferases are transcriptional regulators of nuclear receptors. To 
analyze PXR-associated histone methyltransferase(s) (HMT), we created a cell line 
(PXR-HepG2), by stable transfection of FLAG-tagged human PXR into HepG2 cells, 
which lack PXR (318). The HMT(s) associated with rifampicin-activated PXR were 
detected by co-immunoprecipitation followed by histone methyltransferase assay with 
core histones as the substrates and radiolabeled S-adenosyl-L-[methyl-3H]methionine 
([H3]SAM) as the methyl donor. Methylated histones were detected by autoradiography 
following SDS-PAGE. As shown in Fig. 2.1A, the methyltransferase activity was 
associated with FLAG-tagged PXR in the precipitated complex and the precipitated 
HMT(s) methylated both histones H4 and H2A. 
To identify the amino acid residue(s) methylated by PXRassociated HMT(s), the 
methylated H4 was analyzed by N-terminal sequencing. As shown in Fig. 2.1B, arginine  
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3 (H4R3) was the only methylated residue among the 23 N-terminal amino acids 
analyzed. PRMT1 is the predominant enzyme responsible for this site-specific  
methylation (320). H2A shares the same N-terminal “SGRGK” sequence motif (Fig. 
2.1C) with H4, therefore it was also methylated by PRMT1 (Fig. 2.1A, left lane). 
PRMT5 is another enzyme that methylates H4R3 in this SGRGK motif (321). However, 
PRMT5 is also known to methylate histone H3 (298). Under our experimental 
conditions, we found that major HMT associated with PXR-methylated H2A and H4, 
but not H3. 
It has been reported that acetylation of H4 inhibits methylation of H4R3 by 
recombinant PRMT1 (50). The pre-acetylation on H4K5, K8, K12, or K16 inhibits the 
methylation at similar level (50). However, in our experiments, the pre-acetylation on 
K12 significantly inhibited methylation of H4R3 by the PXR associated complex while 
pre-acetylation on the other lysines was less effective in the inhibition (Fig. 2.1D). The 
recombinant PRMT1 showed the same substrate methylation preference regardless the 
acetylation status of the test peptide. These results suggested that the substrate specificity 
of PRMT1 can be regulated when it is in association with PXR. 
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Fig. 2.1. Histone Histone methyltransferase activity is associated with PXR. A, PXR-HepG2 cells 
were treated with rifampicin (10 μM, 2 h) and used to perform co-immunoprecipitation/HMT assay with 
anti-FLAG antibody. The precipitates and recombinant PRMT1 were subjected to HMT assay, 
respectively, with core histones as the substrates and [3H]SAM as the methyl donor. Methylated histones 
were analyzed by autoradiography. B, methylated H4 in A was subjected to N-terminal sequencing 
analysis. The radioactivity associated with Edman degradation fractions was determined by liquid 
scintillation counting. C, illustration of N-terminal sequences of histone H2A and H4 with the common 
“SGRGK” motif. D, substrate specificity comparison of the PXRassocated HMT and recombinant 
PRMT1. Same molar pre-acetylated H4 N-terminal peptides (0.4 μg, 2 kDa) and recombinant H4 (2 μg, 
11 kDa) (Upstate) were used as the substrates and [3H]SAM was used as the methyl donor. The pre-
acetylated H4 peptides are 20-amino acid N-terminal peptides with K5, K8, K12, or K16 individually 
acetylated. Methylation was detected by autoradiography. 
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2.3.2 Ligand-dependent physical and functional interaction between PRMT1 and PXR 
To analyze the effects of PXR ligand on the interaction between the receptor and 
PRMT1, we performed co-immunoprecipitation assay with the protein extracts of PXR-
HepG2 cells treated with the PXR ligand rifampicin. The complexes precipitated with 
anti-FLAG antibody were eluted with FLAG tag and analyzed by Western blotting. 
PRMT1 was found to associate with PXR in a ligand-dependent manner (Fig. 2.2A). 
To further analyze interactions between PXR and PRMT1 in vivo, we performed 
co-immunoprecipitation assay with liver tissues from VP16-hPXR transgenic mice. In 
these mice, the mouse PXR has been replaced with human PXR, which has been fused 
with VP16 activation domain, resulting in constitutively active PXR in these animals 
(122). PRMT1 was found to specifically associate with PXR as determined by co-
immunoprecipitation followed by Western blot analysis (Fig. 2.2B). 
To further analyze the ligand-dependent PXR-PRMT1 interaction, we performed 
mammalian two-hybrid assay in CV-1 cells. Consistent with the ligand-dependent 
interaction in the co-immunoprecipitation assay (Fig. 2.1A), transient transfection of 
VP16-PRMT1 significantly enhanced the Gal4-PXR-driven luciferase expression upon 
PXR ligand rifampicin treatment (Fig. 2.2C). 
To identify and characterize the interactive domains of PXR responsible for 
association with PRMT1, we performed GST pull-down assay using GST fusion 
peptides containing various domains of PXR (Fig. 2.2D). As shown in Fig. 2.2D, only 
the PXR fragment, which contains the hinge domain and the ligand binding domain, 
interacted with PRMT1. However, the hinge domain alone showed no interaction. Taken  
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Fig. 2.2. PRMT1 interacts with PXR in a ligand-dependent manner. A, PXR-HepG2 cells were treated 
with rifampicin (10 μM, 0, 30, 60, 90, 120 min) and subjected to co-immunoprecipitation with anti-FLAG 
antibodycoupled beads. The precipitates were eluted with 3x FLAG peptide and analyzed by Western 
blotting with PRMT1 antibody. Anti-FLAG antibody blotting was used to show the equal loading of the 
samples. B, liver tissue from a VP16-hPXR transgenic mouse was homogenized in the Co-IP lysis buffer 
and co-immunoprecipitated with goat anti-PXR (lane 4) and rabbit anti-PRMT1 antibodies (lane 3). Goat 
IgG (lane 5) and rabbit IgG (lane 2) were used as negative controls. 1:10 lysate was loaded as the input 
control (lane 1). Precipitates were analyzed by Western blotting with PRMT1 antibody. C, CV-1 cells 
were transfected with the bait plasmid, pBIND-PXR, and the reporter pG5-luc vector, with cotransfection 
of the prey plasmid pACT-PRMT1 or blank pACT plasmid. Six hours after transfection, cells were treated 
with rifampicin (10 μM) or vehicle for an additional 48 h. The interaction was characterized by luciferase 
activity. *, statistically significant difference (t test, p < 0.01). The data are the means + S.D. of three 
independent results. D, mapping of the interactive domains of PXR with PRMT1 by GST pull-down 
assay. Various PXR fragments were fused with GST and the fusion peptides coupled with glutathione-
Sepharose beads were incubated with radiolabeled PRMT1. The precipitated complexes were analyzed by 
autoradiography following SDS-PAGE (middle panel). Upper panel, illustration of PXR fragments. Lower 
panel, loading control of the GST-fused PXR fragments (Coomassie Blue staining). 
 
 53
 
 
 
 
 54
together, these results indicated that PRMT1 specifically associated with PXR ligand-
binding domain, which is consistent with ligand-dependent interactions. The PXR 
interaction appears to be PRMT1-specific. PRMT5 failed to interact with GST-PXR 
fusion peptides in the pull-down assay (data not shown). 
2.3.3 Requirement of PRMT1 for the Transcriptional Activity of PXR 
The PRMT1-null mutation is embryonic lethal in homozygous mice. However, 
mouse embryonic stem cells survived without PRMT1 (322). We utilized these PRMT1 
knock out mouse embryonic stem cells (ES) to analyze the role of PRMT1 in regulating 
PXR transcriptional activity in vivo. Gal4-mPXR (mouse PXR) and Gal4-responsive tk-
UAS-luciferase reporter plasmids were co-transfected into the PRMT1-deficient and 
wild-type mouse ES cells. In the wild-type ES cells, mouse PXR agonist pregnenolone-
16-α-carbonitrile (PCN) induced the PXR-driven luciferase reporter gene, whereas in 
the PRMT1 (-/-) ES cells, PCN was not effective in the induction (Fig. 2.3A). 
To test the effect of PRMT1 on PXR transactivation in human cells, we performed 
PRMT1 knockdown experiment in PXR-HepG2 cells with a small interfering RNA 
(siRNA). The DNA fragment, which encoded a 21-bp hairpin siRNA targeting at 
PRMT1 nucleotides 756 –773 (308) was cloned into the pSilencer vector (Ambion). 
When this siRNA-expressing plasmid was transfected into the PXR-HepG2 cells, the 
PXR ligand-dependent activation of CYP3A4-luciferase reporter gene activity was 
dramatically inhibited (Fig. 2.3B). A similar result was obtained with another siRNA, 
which targets at PRMT1 nucleotides 353–371 (Fig. 2.3C, upper panel). The decreased           
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Fig. 2.3. PRMT1 is required for PXR transcriptional activity. A, PXR activity in PRMT1 (-/-) ES 
cells. Gal4-driven luciferase reporter gene and Gal4-mPXR were transiently transfected into mouse 
PRMT1-null ES cells or wildtype ES cells. The transfected cells were treated with the receptor agonist 
PCN (10 μM, 24 h). Luciferase activity was determined by a luminometer. *, statistically significant 
difference (t test, p<0.01). The data are the means + S.D. of three independent results. B and C, the effect 
of siRNA knockdown of PRMT1 on PXR transcriptional activity. PXR-HepG2 cells were transfected with 
CYP3A4-luciferase. Two siRNAs targeting different sequences of PRMT1 (756–773 and 353–371) were 
used to knockdown PRMT1. Scrambled siRNA was used as the control (B and upper panel of C). The 
total PRMT1 protein expression was analyzed by Western blotting with PRMT1 antibody. Western blot 
with α-tubulin antibody was shown for loading control (C, lower panel). Lane 1, siPRMT1–11; lane 2, 
siPRMT1–28; lane 3, control. The reporter gene expression was measured by luciferase assay. *, 
statistically significant difference (t test, p <0.01). The data are the means + S.D. of three independent 
results. 
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PRMT1 protein expression in siRNA-transfected cells was confirmed by Western 
blotting analysis (Fig. 2.3C, lower panel). 
2.3.4 Recruitment of PRMT1 to the Regulatory Regions of PXR Target Gene CYP3A4 
PXR was identified as the major transcription factor that regulates CYP3A4 through 
binding to the xenobiotic response enhancer module (XREM) which is about 8-kb 
upstream of the transcription starting site (123). The above results of physical and 
functional interactions between PXR and PRMT1 led us to hypothesize that PRMT1 is 
recruited to this regulatory region of CYP3A4 in response to PXR ligand stimulation. 
PXR-HepG2 cells were used in a ChIP assay to analyze the recruitment of PXR and 
PRMT1 as well as changes of histone modifications on the CYP3A4 regulatory region. 
Our results indicated that activation of PXR by rifampicin resulted in recruitment of 
PXR to the regulatory region of CYP3A4 as well as increasing of histone H4 acetylation 
which is indicative of transcriptional activation of the gene. Concomitantly, PRMT1 was 
also recruited to this CYP3A4 regulatory region in response to rifampicin treatment with 
increases in H4R3 methylation (Fig. 2.4). 
2.3.5 Regulation of PRMT1 Subcellular Localization by PXR 
Results from the co-immunoprecipitation/HMT assay indicated that PXR regulates 
PRMT1 substrate specificity (Fig. 2.1D). Because PXR and PRMT1 interacted 
physically and functionally, it is possible that PXR may influence the cellular 
distribution of PRMT1. To test this possibility, we examined the subcellular localization 
of PRMT1 in cells with or without PXR. Interestingly, in human hepatoma cell line 
HepG2 which lacks PXR, PRMT1 was primarily localized in the cytoplasm region. 
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Fig. 2.4. Recruitments of PRMT1, PXR, and changes of histone modifications in the CYP3A4 
regulatory regions in response to PXR activation. PXR-HepG2 cells were treated with rifampicin (10 
μM, 2 h). ChIP assay was performed to analyze the association of PXR, PRMT1, and changes of histone 
H4 acetylation and H4R3 methylation. Results were analyzed by quantitative real-time PCR. *, 
statistically significant difference (t test, p <0.01). The data are the means + S.D. of three independent 
results. 
 
 
However, in PXR-HepG2 cells where PXR is restored, PRMT1 was largely 
localized in the nucleus. Similar effects of PXR on PRMT1 localization were also 
observed in the human intestinal epithelial tumor cell line HT29, which also lacks PXR. 
In these cells, PRMT1 was mainly localized in the cytoplasm. Upon restoration of PXR 
expression by stable transfection, PRMT1 became localized in the nucleus (Fig. 2.5). 
These results suggest that PXR plays an important role in regulating the nuclear 
compartmentalization of PRMT1, which may affect the activity of PRMT1. 
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Fig. 2.5. PXR regulates PRMT1 subcellular localization as determined by immunofluorescence 
microscopy. Parental HepG2 and HT29 cells as well as the PXR stable transfectants PXR-HepG2 and 
PXR-HT29 were analyzed for PXR and PRMT1 subcellular localization by immunofluorescence 
microscopy. 
 
 
 
2.4 SUMMARY AND DISCUSSION 
PRMT1, which methylates arginine 3 of histone H4 (H4R3), is a major arginine 
methyltransferase in mammalian cells. Accumulating evidence indicates that PRMT1 
plays a vital role in physiological and pathophysiological processes including 
development, nuclear receptor regulated gene expression, and oncogenesis (12, 25–27). 
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The mouse homozygous null mutant of PRMT1 is early embryonic lethal, attesting to 
the vital function of PRMT1 in the development and survival of the whole organism 
(23). In addition to modifying histones, PRMT1 methylates non-histone proteins 
involved in DNA repair (28), DNA methylation (29), translational control, and 
maintenance of heterochromatic and euchromatic barrier (30), suggesting that PRMT1 
regulates many aspects of gene expression. At the molecular level, intricate interplay 
between PRMT1 and other histone modification enzymes have been observed. For 
example, methylation of H4R3 by PRMT1 promotes acetylation of histone H4, which 
leads to gene activation; however, acetylation of histone H4 inhibits H4R3 methylation 
(14), suggesting a unidirectional relay of histone marking processes in a transcription 
cycle (15). Based on our results, we propose that by direct interaction with PRMT1, 
nuclear receptors such as PXR initiate target gene transcription by recruiting PRMT1 to 
the regulatory region to accomplish the step of creating methyl marks on the chromatin. 
In this study, we provide strong evidence indicating that PRMT1 is a major histone 
methyltransferase associated with PXR and plays an indispensable role in the 
transcriptional activity of PXR. We used an unbiased biochemical approach with FLAG-
tagged PXR to precipitate the PXR-associated histone methyltransferases in HepG2 
cells. In our Co-IP/methyltransferase assay with core histones H3, H2A, H2B, and H4 as 
substrates, H2A and H4 were methylated by the PXR-associated HMTs. We sequenced 
the N-terminal 23 amino acids of methylated H4 and found that H4R3 was the major 
methylated residue. The methylated H2A was most likely due to the common “SGRGK” 
motif shared by these peptides (Fig. 2.1C). 
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The results of Co-IP in both mouse liver tissue and PXR transfected HepG2 cells 
indicated that PXR interacts with PRMT1. GST pull-down assay strongly suggested that 
the direct interaction between PXR and PRMT1 is through the PXR ligand binding 
domain. As indicated by the ChIP assay results, this direct interaction may play a role in 
recruitment of PRMT1 to the CYP3A4 regulatory region, where it promotes transcription 
through methylation and acetylation of chromatin as demonstrated in Fig. 2.4. Another 
possibility is that by direct contact, PRMT1 methylates PXR and thus modifies its 
transactivation. For example, HNF-4α is methylated by PRMT1 and thus changes its 
activity in gene regulation (25). We have tested this possibility by performing PRMT1 
methyltransferase assay with GST-PXR as the substrate. In this assay, PRMT1 did not 
methylate the GST-PXR fusion peptide (data not shown). 
The important role of PRMT1 in the transcriptional activity of PXR was further 
confirmed using two approaches: 1) knockdown of PRMT1 expression by PRMT1-
specific siRNA drastically inhibited the PXR-regulated luciferase reporter gene activity, 
and 2) in PRMT1 (-/-) cells PXR transcriptional activity was not detectable, suggesting 
an indispensable function of PRMT1 for the PXR-regulated gene expression. 
Interestingly, our results indicate that PXR also regulates the functions of PRMT1in 
at least two aspects. Firstly, PXR regulates the PRMT1 substrate specificity. In 
comparison with recombinant PRMT1, the PXR-associated PRMT1 demonstrated 
preference for certain pre-acetylated H4 peptides; whereas pre-acetylation of H4K12 is 
inhibitory to methylation of H4R3 by PRMT1 (Fig. 2.1D), acetylation of H4K5, H4K8, 
and H4K16 has no effect on the H4R3 methylation. Secondly, the presence of PXR has a 
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significant effect on the cellular compartmentalization of PRMT1. In normal human 
hepatocytes that express PXR, PRMT1 is primarily localized in the nucleus (data not 
shown); however, in HepG2 cells that lack PXR, PRMT1 is localized mostly in the 
cytoplasm (Fig. 2.5). Stable transfection of PXR restores the PXR responses (5, 24), and 
PRMT1 is localized in the nucleus as demonstrated in this study (Fig. 2.5), suggesting 
PXR plays an important role in PRMT1 nuclear translocation. However, it is possible 
that this phenomenon is unique to hepatocytes, and PXR overexpression causes PRMT1 
nuclear translocation. To further analyze the role of PXR in PRMT1 nuclear 
translocation, we extend this observation to another cell line.We transfected PXR into 
colon epithelial cancer cell line HT29, which doesn’t express endogenous PXR (Fig. 
2.5). Similar to HepG2 cells, PRMT1 also translocated from cytoplasmic region into 
nucleus with PXR expression, further supporting the role of PXR in nuclear localization 
of PRMT1 (Fig. 2.5). 
Taken together, these results suggest that interaction between PXR and PRMT1 is 
reciprocal and PRMT1 not only regulates PXR transcriptional activity, but PXR also 
regulates the activity of PRMT1 through controlling its cellular compartmentalization in 
addition to substrate preferences. The effects of PXR on PRMT1 suggest that PXR has a 
rather general effect on the cellular processes that require PRMT1 and furthermore, the 
function of PXR may go beyond the xenobiotic/drug metabolism to include many 
aspects of physiological/pathophysiological processes which require PRMT1. 
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CHAPTER III 
PRETREATMENT WITH DMSO GIVES A PRIMING EFFECT ON PXR 
TRANSACTIVATION 
 
3.1 OVERVIEW 
Prior exposure to chemicals/agents may alter epigenome in such a way that 
subsequent exposure to the same or different xenobiotic would produce different 
response. This phenomenon has been observed in a differentiation study of leukemia 
HL-60 cells: Pre-exposure to 1-2% dimethyl sulfoxide (DMSO) for 24 h caused much 
more rapid differentiation upon 9-cis-retinoic acid stimulation than 9-cis-retinoic acid 
treatment alone (323).  
In this study, we demonstrated a similar “priming” effect for PXR-regulated gene 
expression. Upon pre-exposure to 1.25-2.5% DMSO, PXR-mediated CYP3A4 induction 
by rifampicin was significantly increased campared to “naïve” cells, which were not pre-
exposed. Obviously, understanding the underpinning mechanism of this “priming” effect 
has important implications for xenobiotic/drug metabolism and detoxification, drug-drug 
interactions as well as therapeutic application of drug combinations.  
Post-translational modifications on the N-termini of histones have been shown to 
play critical roles in gene regulation. In our previous study, PRMT1 (protein arginine 
methyltransferase 1) was demonstrated to be an essential coactivator for PXR-mediated 
gene regulation. In this study, PRMT1 was also determined to play an important role in 
the priming process. The priming effect was enhanced by PRMT1 overexpression and 
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abolished when PRMT1 was knocked down. Inhibition of methyltransferase activity by 
ADOX before priming also inhibited the priming effect while ADOX treatment after 
priming had no effect.  
The combination and interplays of histone modifications has been shown to create a 
marking system (“histone code”), which is part of the epigenetic mechanisms for gene 
regulation (205). Recent evidence showed that modification marks usually prevent the 
adjacent arginine to be methylated. For example, H3K9 acetylation inhibits H3R8 
methylation (298). H3R8 methylation inhibits H3K9 methylation (312). H4R3 
methylation by PRMT1 was reported to set the stage for subsequent histone 
modifications in vivo (286) and facilitate H4 acetylation by p300 in vitro (50). However, 
acetylation of H4 inhibits recombinant PRMT1 methylation on H4R3 (50). In our 
previous study, preacetylation of H4K12 but not lysines 5, 8 and 16 inhibited PXR-
associated PRMT1 methylation of H4R3 in an in vitro histone methyltransferase assay. 
In this study, we observed an in vivo decrease of H4K12 acetylation in the CYP3A4 
promoter region upon rifampicin or priming stimulation. This observation also fit our 
hypothesis that, to complete the transcription cycle, specific acetylation has to be 
removed to allow H4R3 methylation, which facilitates total histone acetylation.  
Treatment with 2% DMSO for 24 h also induced a G0/G1 arrest in HepG2 cells 
regardless of PXR expression. This observation suggested that 24 h treatment of 2% 
DMSO not only alters histone modifications on regulatory region of selective genes, but 
also exhibits a global impact on cellular physiological process.  
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3.2 MATERIALS AND METHODS 
3.2.1 Materials 
DMSO, rifampicin, TSA, ADOX and anti-FLAG M2 antibody are from Sigma. 
Anti-acetyl-(pan)H4, anti-acetyl-H3, anti-acetyl-H4K8, and anti-acetyl-H4K12 
antibodies were purchased from Upstate (Millipore, Billerica, MA). Anti-methyl-H4R3 
is from Abcam (Cambridge, MA). Isotype IgGs were from Santa Cruz Biotechnology 
(Santa Cruz, CA). 
3.2.2 Cells 
HepG2 and HepG2 derived cells were cultured in DMEM (Dulbecco’s modified 
Eagle’s medium) (HyClone, Logan, UT) supplemented with 10% FBS (fetal bovine 
serum) (Sigma) and 1x antibiotic and antimycotic (Invitrogen, Carlsbad, CA). PXR-
HepG2 and reporter-HepG2 stable transfectants were created as described in (318). In 
brief, HepG2 cells are stably transfected with 3x Flag-PXR plasmid to create PXR-
HepG2 cells and cotransfected with neo-PXR and PXR-directed reporter plasmid pGL3-
3A4-Luc (318) to create reporter-HepG2 cells.  
Cell suspensions of primary human hepatocytes was purchased from Cambrex 
BioScience (Walkersville, MD). Upon arrival, the cells were resuspended in DMEM 
medium supplemented with 5% FBS, 1x antibiotic and antimycotic, 4 μg/ml insulin, and 
1μM dexamethasone, and plated in collagen coated 12-well plates. After seeded, cells 
were maintained in WEM containing ITS+, 0.1 μM dexamethasone and 1x antibiotic 
overnight.  
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3.2.3 Transient transfection and Luciferase assay 
Cells were seeded in 12-well plates. When growth reached 50% confluence, cells 
were transfected with plasmid DNA for 12 h using Lipofectamine (Invitrogen). The 
transfected cells were treated with chemicals or vehicle accordingly. The luciferase 
assay was performed using a luciferase assay system kit, according to the manufacturer’s 
recommendation (Promega). 
3.2.4 Statistical analysis 
Statistical evaluations were conducted using two-tailed t test with triplicates for 
each treatment. A p value of less than 0.01 was considered to be statistically significant. 
Data are the means + S.D. of three independent results. 
3.2.5 Real time PCR 
Total RNA was extracted using the Trizol reagent according to the manual 
(Invitrogen). Reverse-transcription was performed with an M-MLV reverse transcriptase 
kit with random primers (Invitrogen). The amount of complementary DNA template was 
determined by real-time quantitative PCR in triplicates with a 1-μl sample. 
Amplifications were performed in the 7500 Fast Real-Time PCR System (Applied 
Biosystems, Foster City, CA) with SYBR Green Master Mix (Applied Biosystems).  
3.2.6 Small interfering RNA 
The small interfering RNA-expressing plasmid were constructed by cloning the 
sequence targeting PRMT1 at coding region sequence 756–773 (308) (siPRMT1) into 
pSilencer 5.1 plasmid according to the manual (Ambion). The targeting plasmid was 
created by inserting 5’-GATCCGATCCACTGGTGGGAGAACTTCAAGAGAGTT 
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CTCCCACCAGTGGATTTTTTTGGAAAAGCT-3’ (siPRMT1). The siRNA plasmid 
and the scramble siRNA control were transfected into PXR-reporter-HepG2 cells. The 
transfected cells were treated with rifampicin (10 μM, 48 h).  
3.2.7 Chromatin Immunoprecipitation (ChIP) 
ChIP assay was performed according to the manufacturer’s protocol from Upstate, 
using the ChIP assay kit with modifications. Briefly, after treatment, cells were cross-
linked with 1% formaldehyde for 15 min at room temperature, and then the reaction was 
stopped by incubating in glycine with a final concentration of 0.125 M for 5 min. Cells 
were washed three times with cold PBS and harvested by scraping with cell scraper. 
Then the cells were lysed in the SDS lysis buffer (1% SDS, 10 mM EDTA, and 50 mM 
Tris-HCl, pH 8.1) on ice for 10 min. The samples were sonicated into DNA fragments of 
0.2–1 kb (checked by agarose gel electrophoresis/ethidium bromide staining) and 
microcentrifuged at maximal speed for 10 min at 4°C. The supernatant was precleared 
by rotating with 60 μl of Salmon Sperm DNA/protein-agarose slurry for 30 min at 4°C 
and then aliquoted after centrifugation. 20 μl was saved as input and 200 μl (equal to 
one-fifth the amount of cells from one 100% confluent 15-cm dish) was used for each 
antibody. Each 200-μl supernatant aliquot was diluted with 800 μl of ChIP dilution 
buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8.1, and 
167 mM NaCl) and incubated with the specific antibody (1 μg/sample) at 4°C overnight. 
A mock precipitation without antibody was used as negative control. The next day, 60 μl 
of salmon sperm DNA/protein-agarose slurry was added to each sample and incubated at 
4 °C for another 2–4 h. The beads were then washed for 3–5 min with 1 ml of each 
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buffers listed: low salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM 
Tris-HCl, pH 8.1, 150 mM NaCl), high salt wash buffer (0.1% SDS, 1% Triton X-100, 2 
mM EDTA, 20 mM Tris-HCl, pH 8.1, 500 mM NaCl), and LiCl wash buffer (0.25 M 
LiCl, 1% IGEPAL-CA630, 1% deoxycholic acid (sodium salt), 1 mM EDTA, 10 mM 
Tris-HCl, pH 8.1). After all washes, pellets were suspended by vertex with 150 μl of 
freshly prepared elution buffer (0.1 M NaHCO3, 1% SDS) for 15 min, and then 
supernatant was collected. This elution progress was repeated once again, and in total 
300 μl elutes were collected. The one-tenth input was diluted with dilution buffer to a 
total volume of 300 μl. Elutes and diluted inputs were incubated in 0.3 M NaCl at 65 °C 
for 4 h to reverse formaldehyde cross-linking. Then 10 μl of 0.5 M EDTA, 20 μl of 1 M 
Tris-HCl, pH 6.5, and 20 μg of proteinase K were added to the sample and incubated at 
45 °C for 1 h. DNA was extracted with phenol/chloroform and then incubated with 10 
μg of glycogen in 75% ethanol at -20 °C overnight. After precipitation by centrifuging at 
12,000 x g for 30 min at 4 °C, the recovered DNA pellets were dissolved in 30 μl of 
distilled water. The DNA target in the sample was determined by PCR. 
3.2.8 Cell cycle analyzed by flow cytometry 
After treatment, cells were harvested with trypsinization and fixed in 70% ethanol 
for 2 h. After washing with PBS, cells were resuspended in Propidium Iodide/PBS 
staining solution (2 μg/ml) supplemented with 0.1 mg/ml RNase and incubated for 30 
min at room temperature. Flow cytometry analysis was performed with an FACS Calibur 
flow cytometer (Becton Dickinson) with the excitation at 488 nm and the emission at 
520 nm.  
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3.2.9 GST pull-down assay 
The GST pull-down assay was performed as described (52). Briefly, [35S]methionine-
labeled fulllength PRMT1 protein was generated with a TNT-coupled Reticulocyte 
Lysate System (Promega) using the SP6 promoter-driven cDNA plasmid as the template. 
PCR-generated RXR cDNA fragments were inserted in-frame into pGEX-5X-3 
(Amersham Biosciences). The plasmids were expressed in Escherichia coli (BL21), and 
fusion polypeptides were purified with glutathione-Sepharose 4B beads (Amersham 
Biosciences) according to the manufacturer’s instruction. Twenty micrograms of each 
fusion polypeptide (estimated by comparison with bovine serum albumin in an SDS-
PAGE gel with Coomassie Blue staining) was incubated with 20 μl of radiolabeled 
PRMT1 in a total volume of 200 μl of binding reaction buffer (20 mM Hepes pH 7.9, 
1% Triton X-100, 20 mM dithiothreitol, 0.5% bovine serum albumin, and 100 mM KCl) 
for 3 h at 4 °C. After incubation, beads were washed three times with the same buffer 
without bovine serum albumin. The bound proteins were eluted by boiling in the SDS-
PAGE sample buffer and resolved by 12% SDS-PAGE gel electrophoresis. The signals 
were detected by autoradiography. The input control was 2 μl of the radioactive PRMT1. 
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3.3 RESULTS 
3.3.1 Pretreatment of DMSO increased the PXR transactivatity upon ligand treatment.  
To investigate the “priming” effect on PXR-regulated gene expression, we utilized 
HepG2 cells stably transfected with human PXR and CYP3A4 driven luciferase reporter 
gene (reporter-HepG2) to analyze the effect of DMSO on rifampicin (RIF) induced PXR 
transcriptional activity. Pretreatment with 1.25% or 2.5% DMSO overnight significantly 
increased PXR-regulated CYP3A4-luciferase activation by rifampicin (Fig. 3.1A). 
We also investigated this “priming” effect in primary human hepatocytes. Upon 
rifampicin activation, CYP3A4 mRNA level was also significantly elevated when cells 
were pretreated with 1.25% or 2.5% DMSO (Fig. 3.1B). The effect decreased at a higher 
dose namly, 5% for the cell line and 2.5% for primary hepatocytes. That might be due to 
the susceptibility difference between the cell line and the primary hepatocytes. 
In order to characterize the priming effects, we tested different pre-exposure times 
for DMSO. Pretreatment with DMSO for 9 h gave a significant “priming” effect. As the 
pre-exposure to DMSO was prolonged, the priming effect was enhanced (Fig. 3.2A), 
indicating that priming is not only dose- but also time-dependent. 
We performed another experiment in which cells were pretreated with 2.5% DMSO 
for 18 h. DMSO was then withdrawn and rifampicin was added immediately or after a 
certain period (24, 48 or 72 h). After a 48 h interval, the priming effect was still 
significant (Fig 3.2B, compare second and the fourth lanes of 48 h); however, after 72 h, 
primed and naive cells had no significant difference in PXR target gene induction. In 
conclusion, the priming effect can persist for up to 48 h. 
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Fig. 3. 1. DMSO pretreatment enhanced the PXR transcriptional activity. (A) HepG2 cells were 
stably transfected with PXR and CYP3A4-luciferase reporter gene. Cells were exposed to DMSO for 18 h. 
DMSO was withdrawn and cells were exposed to 10 μM RIF. Luciferase activity was measured 48 h later. 
*, statistically significant difference (p<0.05). The data are the means±S.D. of three independent 
measurements. (B) Human primary hepatocytes were seeded in 12 well plates. Cells were treated with 
DMSO and after 18 h DMSO was withdrawn. Cells were exposed to 10 μM RIF. Cyp3a4 mRNA level 
was measured 24 h later by real-time quantitative RT-PCR.   
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Fig. 3.2. Priming was time and dose dependent and persisted for 48 h. (A) Reporter-HepG2 cells were 
exposed to DMSO for indicated duration and then to 10 μM RIF without DMSO. Luciferase activity was 
measured 48 h later. (B) Cells were treated with 2.5% DMSO and after 24 h DMSO was withdrawn. After 
indicated hours, cells were treated with 10 μM RIF. Luciferase activity was measured 48 h later. *, 
statistically significant difference (p<0.05). The data are the means ± S.D. of three independent 
measurements.   
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3.3.2 Pretreatment of DMSO altered histone modifications in the regulatory region of 
PXR target gene 
        To understand the epigenetic mechanisms of the priming effect, we used PXR-
HepG2 cells, that are HepG2 cells stably transfected with 3x Flag-PXR, to perform the 
ChIP assay. Primed and naïve cells treated with rifampicin or vehicle were harvested and 
ChIP assay was performed as described in the method. We analyzed several histone 
modifications in the CYP3A4 proximal promoter and a distal xenobiotic response 
enhancer module (XREM) about 8 kb upstream of the transcriptional starting site. PXR 
was shown to regulate CYP3A4 expression through binding to these regions (123). As 
shown in Fig. 3.3, in both regulatory regions, total acetylation of H3 and H4 correlated 
with target gene activation that was increased upon rifampicin treatment and further 
enhanced upon priming. The difference was that basal acetylation of H4 was higher than 
H3. As an active transcription mark essential for histone acetylation (286), methylation 
of H4R3 was also increased upon rifampicin and significantly enhanced upon priming.  
Although total acetylation of H4 was correlated with gene activation, acetylation at 
selective lysines gave different correlations. Acetylation of lysine 8 was not changed by 
rifampicin treatment or pretreatment of DMSO. However, acetylation of lysine 12 was 
significantly decreased in both regions in naïve cells upon rifampicin activation. In our 
previous study, we detected an inhibitory effect on PXR-associated PRMT1 methylation 
of H4R3 by preacetylation of H4K12, while preacetylation on other lysines did not have 
this inhibition. Therefore, removal of H4K12 acetylation may facilitate H4R3 
methylation for PXR target gene activation. 
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Fig. 3.3. DMSO priming altered histone modifications in the cyp3a4 regulatory regions.  PXR-HepG2 
cells were treated with/without 2% DMSO for 24 h and then with 10 μM rifampicin or vehicle for 2 h. 
Histone modifications were analyzed by ChIP assay with indicated antibodies. XREM, xenobiotic 
response module; ER6-TATA, proximal promoter region.  
 
 
3.3.3 PRMT1 played an important role in the priming   
PRMT1 is the major protein arginine methyltransferase in mammalian cells which 
selectively methylates H4R3. In our previous study, we demonstrated that PRMT1 is an 
important PXR coactivator which associates with PXR in vitro and in vivo. To 
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investigate whether PRMT1 played a role in this PXR-mediated priming effect, we 
transiently transfected PRMT1 expression plasmid into the reporter-HepG2 cells. 
Results are shown in Fig. 3.4A. The rifampicin induction of CYP3A4-luciferase 
expression was not influenced by overexpression of PRMT1, which indicated a saturated 
endogenous PRMT1 level for PXR-mediated gene activation. However, the priming 
effect was enhanced by PRMT1 transfection in a dose-dependent manner.  
    We also knocked down PRMT1 by expressing small interference RNA of PRMT1 
(siPRMT1) in the reporter-HepG2 cells. Knockdown of PRMT1 decreased rifampicin 
induction of CYP3A4-luciferase expression in both unprimed “naïve” and primed 
reporter-HepG2 cells dose-dependently (Fig. 3.4C). Transfection of a control scramble 
siRNA did not influence either CYP3A4-luciferase induction or the priming effect (Fig. 
3.4D). However, the priming effect on induction of CYP3A4 mRNA level is more 
sensitive to PRMT1 knockdown. Transient transfection of a moderate amount of 
siPRMT1 abolished the priming effect without significant decreasing induction of 
CYP3A4 mRNA in naïve cells (Fig. 3.4B).  In conclusion, pretreatment with DMSO 
sensitized cells to ligand-dependent activation of PXR also to expression of the 
coactivator PRMT1. PRMT1, an essential PXR coactivator, is also important in this 
priming process. 
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Fig. 3.4. PRMT1 played an important role in the priming effect. (A) HepG2 cells which stably express 
PXR and cyp3a4-luc were transiently transfected with PRMT1 plasmid (0, 0.1, 0.2, or 0.4 μg/ml). 
Transfected cells were pretreated with (primed) or without (naïve) 2% DMSO for 24 h and then exposed 
to rifampicin (10 μM). Luciferase activity was measured 48 h later. (B) Reporter-HepG2 cells were 
transiently transfected with 0.05 μg/ml siPRMT1 or scramble siRNA. Primed and naïve transfected cells 
were treated with 10 μM rifampicin. After 24 h, CYP3A4 mRNA level was determined by quantitative 
real-time PCR. (C and D) Reporter-HepG2 cells were transiently transfected with siPRMT1 (C, 0, 0.05, 
0.1, or 0.2 μg/ml) or control scrambled siRNA (D, 0, 0.1 or 0.2 μg/ml). Primed or naïve transfected cells 
were exposed to 10 μM rifampicin. Luciferase activity was measured 48 h later. *, statistically significant 
difference (p<0.05). The data are the means±S.D. of three independent measurements. 
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3.3.4 Histone modifications played a critical role in the priming effect 
We demonstrated that PRMT1 played an important role in the priming and we also 
observed significantly elevated H4R3 methylation in primed cells treated with 
rifampicin. In order to investigate the importance of the methyltransferase activity for 
priming effect, we treated reporter-HepG2 cells with ADOX, an inhibitor of 
methyltransferase (274,320). As shown in Fig. 3.5, treatment with ADOX before 
priming inhibited the priming effect. However, treatment with ADOX after priming did 
not significantly change the PXR transactivation. These data indicated a critical role for 
methyltransferase activity. Although we demonstrated an important role for PRMT1 in 
the priming effect, we cannot rule out other methyltransferases in this process.   
We observed reduced H4K12 acetylation in the promoter region upon DMSO 
pretreatment. Therefore, histone deacetylases (HDACs) may be important for the 
priming effect. We treated reporter-HepG2 cells with TSA, an HDAC inhibitor (Fig. 
3.6). Since HDAC is inhibited, total histone acetylation was increased and TSA 
enhanced induction of luciferase expression by rifampicin. However, the priming effect 
was abolished when cells were exposed to TSA before priming. This demonstrates that 
HDACs played a significant role in the priming. Accumulated acetylation of H4 also 
inhibited H4R3 methylation, indirectly indicating the importance of H4R3 methylation. 
However, treatment of TSA after priming further elevated the PXR transactivation (Fig. 
3.6B). 
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Fig. 3.5. Inhibiton of methyltransferase activity by Adox abolished the priming effect while the same 
treatment post priming had no impact. (A) Adox was added to reporter-HepG2 cells 24 h before 
priming. (B) Cells were primed with 2% DMSO for 24 h and then treated with Adox for 24 h. After these 
treatments, cells were treated with rifampicin. Luciferase activity was measured 48 h later. *, statistically 
significant difference (p<0.05). The data are the means±S.D. of three independent measurements.  
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Fig. 3.6. HDAC inhibitor TSA inhibited priming effect while the same treatment post priming 
enhanced it. (A) Reporter-HepG2 cells were exposed to TSA 24 h before priming. (B) Cells were treated 
with TSA after priming. Then cells were treated with rifampicin. Luciferase activity was measured 48 h 
later. *, statistically significant difference (p<0.05). The data are the means±S.D. of three independent 
measurements.  
 
 
3.3.5 Treatment with 2% DMSO stimulated G0/G1 arrest in HepG2 cells 
In order to determine whether 2% DMSO can influence cell cycle, we stained HepG2 
and reporter-HepG2 cells with propidium iodide and performed flow cytometry. As 
shown in Fig. 3.7, percentage of cells at G0/G1 phase was significant higher in cells 
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treated with 2% DMSO for 24 h compared to untreated cells in spite of their expression 
of PXR (82.61% v.s. 70.29% for reporter-HepG2 and 81.49% v.s. 60.69% for HepG2).  
 
 
 
Fig. 3.7. DMSO treatment caused G0/G1 arrest. HepG2 cells with or without stably transfected PXR 
were treated with 2% DMSO for 24 h. Cells without treatment (naïve) were used as a control. Cells stained 
with Propidium Iodide (P.I.) were subjected to flowcytometry analysis.  
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3.4 SUMMARY AND DISCUSSION 
DMSO was the first chemical discovered to induce growth arrest and terminal 
differentiation of murine erythroleukemia cells (324). Later studies on DMSO and other 
polar solvents which cause the same effect elicited discovery and development of cancer 
therapeutic compounds that exhibit histone deacetylase activity (325). Histone 
modification activity for DMSO was not reported, however, several histone modification 
changes were identified at RAR targeted promoters in HL-60 leukemia cells treated with 
2% DMSO for 16-24 h (323).  
Although the effects of DMSO on leukemia cells have been studies for over 35 
years, the influence of this solvent on other cell types was not clear. DMSO is a polar 
solvent widely used in biological and medical science. It is a cryoprotectant for 
preserving cell, organs, tissues and embryos. However, the physiological effects of 
DMSO on exposed cells or organs have not been extensively investigated. Although 
DMSO has FDA-approved therapeutic applications for many inflammatory conditions, 
such as treatment for interstitial cystitis, not much information on its mechanism has 
been reported.   
In this study, we demonstrated that DMSO pretreatment can “prime” the PXR-
regulated gene expression resulting in increased responses to PXR ligands (Fig. 3.1). 
This effect was DMSO-dose and treatment duration (time) dependent (Fig. 3.2). 
Although high dose DMSO reduced the effect, which may be due to toxicity, the effect 
seemed to be enhanced as the treatment was prolonged. DMSO is usually used as a 
vehicle control in culture studies at the dose as low as 0.1 or 0.2%. However, when cells 
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were exposed to this vehicle control for long periods, some effect are observed. Human 
primary hepatocytes can also be sensitized by 1.25% DMSO to PXR ligand activation 
(Fig. 3.1B). This data provided evidence for the priming effect in primary hepatocyte 
and this may have important implications for drug-drug interactions or drug combination 
therapy. 
Mechanistically, priming may involve an epigenetic mechanism through alteration 
of histone modifications (Fig. 3.3). The fact that the priming effect lasts longer than one 
mitotic division (average 24 h, ATCC) is consistent with this notion (Fig. 3.2B). Total 
acetylation of H4 and H3, which was increased by rifampicin, was enhanced by priming, 
correlated with the transcription level of cyp3a4 expression. Methylation on H4R3 was 
significantly increased upon rifampicin treatment in primed cells compared to naïve cells 
(Fig. 3.3).  
PRMT1 is a required co-regulator for PXR as demonstrated by our previous study. 
Methylation of H4R3 by PRMT1 has been shown to set the stage for subsequent 
acetylation (286). However, acetylation, in turn, inhibits H4R3 methylation (50), 
suggesting an intricate interaction between histone marking system (histone code) which 
may be a “feed-back” inhibition mechanism to fine-tune the PXR-regulated responses 
(317). Based on this observation, we propose a model of transcription “relay” (Fig. 8) to 
depict the methylation and acetylation interaction (317). Our results with the Adox and 
TSA treatments are also consistent with this model (Fig. 3.5 and 3.6).  
The key points are the followings: 1. methylation of H4R3 by PRMT1 is critical for 
the priming effect, since this methylation was significantly increased upon rifampicin 
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stimulation after priming (Fig. 3.3). The priming effect was enhanced by overexpression 
of PRMT1 and inhibited by knockdown of PRMT1 as well as Adox pretreatment. 
However, Adox treatment had no significant effect after priming (Fig. 3.2 and 3.5). 
PRMT1 was also demonstrated to play an important role in the priming of leukemia HL-
60 cells through RAR-mediated gene regulation. We demonstrated a direct interaction 
between PRMT1 and RXR by GST pull-down assay (Fig. 3.8). RXR ligand binding 
domain is the interactive domain binding to PRMT1. RAR and PXR both formed 
heterodimers with RXR to regulate target genes. We hypothesized that all nuclear 
receptors which form heterodimers with RXR can recruit PRMT1 and be sensitized by 
priming. Further verification of this hypothesis is currently being investigated. 2. The 
sequence of modifications is important i.e. methylation to acetylation is unidirectional 
and in order to complete transcription, the acetylation mark needs to be removed by 
HDAC. Furthermore, in our previous study, we demonstrated that H4K12 acetylation 
strongly inhibited the methylation of H4R3 by PXR-associated PRMT1. This is 
consistent with decreased H4K12 acetylation upon treatment with rifampicin and upon 
priming in the promoter region (Fig. 3.3). This observation also supports our 
transcription “relay” model that lysine acetylation needs to be removed for re-
methylation of H4R3. Our results demonstrate that HDAC activity directed at a specific 
residue, whereas HDACs usually deacetylate multiple residues. TSA treatment before 
priming, prevented removal of H4K12 acetylation, and inhibited the priming effect. 
After H4K12 deacetylation is finished after priming, TSA treatment had no effect on 
H4K12 acetylation and H4R3 methylation. However, inhibition of other HDACs caused 
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further accumulation of H3 and H4 acetylation which correlated with higher gene 
activation.  
 
 
 
Fig. 3.8. RXR interacted with PRMT1 through its ligand binding domain. Full-length RXR and 
various RXR fragments were fused with GST and the fusion peptides coupled with glutathione-Sepharose 
beads were incubated with radiolabeled PRMT1. The precipitated complexes were analyzed by 
autoradiography following SDS-PAGE (middle panel). Upper panel, illustration of RXR fragments. Lower 
panel, loading control of the GST-fused RXR fragments (Coomassie Blue staining). 
 
 
An unexpected difference on H4K12 acetylation after priming was observed 
between CYP3A4 enhancer and promoter regions. Acetylation of H4K12 at the enhancer 
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region was significantly reduced upon treatment with rifampicin. However, this change 
did not occur after priming. In contrast, H4K12 acetylation at the promoter region was 
significantly reduced upon treatment with rifampicin or priming. In another study from 
our laboratory, we demonstrated a looping structure between CYP3A4 enhancer and 
promoter regions upon rifampicin activation. Based on this observation, we 
hypothesized that without priming, rifampicin stimulated the looping structure and also a 
recruitment of HDAC to deacetylate H4K12. As the looping structure is formed, HDAC 
is able to approach the substrate on both the enhancer and promoter regions. After 
H4K12 is deacetylated, PRMT1 methylates H4R3 and to facilitate the subsequent 
acetylation of H4 and H3. However, upon priming, HDAC is recruited only to the 
promoter region to deacetylate H4K12. After the looping structure is formed, PRMT1 
can methylate H4R3 without recruitment of the HDAC to deacetylate H4K12. Therefore, 
the acetylation of H4K12 at the enhancer region is not removed after priming.  
Our explanation is based on the histone modification changes that were observed. 
There may be other histone modifications playing a role in the priming process, such as 
H3K4 and H3K9 methylation.  
Thus 2% DMSO treatment for 24 h not only changes histone modifications on 
selective target gene regulatory regions, but also caused some global physiological 
effects, including G0/G1 arrest of HepG2 cells which was independent of PXR. This 
data suggests that this cell cycle regulation is global and at the level of epigenome 
modification. 
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CHAPTER IV 
SUMMARY AND CONCLUSION 
 
4.1 PRMT1 PLAYS AN IMPORTANT ROLE IN PXR MEDIATED GENE 
REGULATION 
PXR is a ligand-dependent transcription factor, regulating gene expression of 
enzymes and transporters involved in xenobiotic/drug metabolism. Ligand-activated 
PXR binds to cognate response elements in the upstream regulatory regions of target 
genes, such as CYP3A4 as heterodimer with RXR, and recruits coactivators to initiate 
target gene activation (123). PRMT1 regulates expression of numerous genes, including 
nuclear receptor-regulated transcription, through methylating histone and non-histone 
proteins. It is a coactivator of several nuclear receptor-mediated genes (50,316). The first 
objective of this study, we reported that PRMT1 is required for the transcriptional 
activity of PXR. Co-immunoprecipitation and histone methyltransferase assays revealed 
that PRMT1 is a major histone methyltransferase associated with PXR. It was reported 
that  nuclear receptor coactivator SRC-1 recruited PRMT1 as a secondary coactivator 
(123). However, our study shows a direct interaction between PXR and PRMT1, 
determined by glutathione S-transferase (GST) pull-down assays. GST pull-down assay 
also shows that the PXR ligand-binding domain is necessary for PXR-PRMT1 
interactions, which is consistent with the ligand dependent association determined by 
mammalian two-hybrid and coimmunoprecipitation. Coimmunoprecipitation of PRMT1 
with PXR in the humanized mouse liver gives in vivo evidence for their association.  
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In eukaryotes, DNA is packaged in chromatin with histones and several nonhistone 
proteins. In order to recruit transcriptional machinery to initiate gene expression, 
chromatin needs to be remodeled and modifications of histone N-terminal tails are 
important for this process (203). These modifications include acetylation, methylation, 
phosphorylation, and ubiquitylation. Acetylation of histones is correlated to gene 
activation (209,219), whereas methylation of histone lysine residues is related to both 
gene activation and corepression (249,252,256). Arginine methylation of histones also 
plays role in gene activation or repression through methylating N-terminal tails of 
histones in the promoter or other regulatory regions (50,205,278,294,295). In our study, 
the chromatin immunoprecipitation (ChIP) assay shows that PRMT1 is recruited to the 
regulatory region of the PXR target gene CYP3A4, with a concomitant methylation of 
arginine 3 of histone H4, in response to the PXR agonist rifampicin. In mammalian cells, 
small interfering RNA (siRNA) knockdown and gene deletion of PRMT1 greatly 
diminished the transcriptional activity of PXR, suggesting an indispensable role of 
PRMT1 in PXR-regulated gene expression.  
Interestingly, PXR appears to have a reciprocal effect on the function of PRMT1 by 
regulating its cellular compartmentalization as well as its substrate specificity. Without 
PXR, PRMT1 localized in the cytoplasm of HepG2 and HT-29 cells while PXR 
expression caused PRMT1 to translocate into the nucleus. Recombinant PRMT1 
methylation on H4R3 is slightly inhibited by preacetylation of H4 lysine 5, 8, 12 and 16 
at the same level. However, methylation of H4R3 by the PXR-associated complex is 
selectively inhibited by preacetylation of H4K12. Single acetylation of other lysines 
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does not inhibit the methylation. We did not determine whether combined acetylation 
causes synergistic inhibition on H4R3 methylation, which was previously reported by 
Wang et., al (50). This in vitro inhibition may have implications regarding epigenetic 
mechanisms of gene regulation. 
Taken together, these results demonstrated mutual interactions and functional 
interplay between PXR and PRMT1, and this interaction may be important for the 
epigenetics of PXR-regulated gene expression. 
 
4.2 PRMT1 PLAYS AN IMPORTANT ROLE IN PXR MEDIATED PRIMING 
EFFECT 
Prior exposure to chemicals/reagents may alter subsequent response to the same or a 
different reagent. This hypothesis has important implications in xenobiotic/drug 
metabolism and detoxification, drug-drug interactions as well as therapeutic application 
of drug combinations.  
DMSO has long been used to stimulate myeloid differentiation of leukemia cells. It was 
shown to induce hemoglobin expression in HL-60 leukemia cells (324). In addition, a 
“priming” phenomenon was demonstrated in HL-60 differentiation that HL-60 cells 
preexposed to 1-2% DMSO for 24 h differentiate much more rapid upon 9-cis-retinoic 
acid stimulation than 9-cis-retinoic acid treatment alone (326). A recent study 
demonstrated epigenetic changes, namely histone modification changes in RAR target 
gene regulatory regions during the “priming” process and have suggested the 
involvement of PRMT1 in the priming phenomenon (323).  
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In our research, we studied how priming by DMSO influences the PXR-mediated 
activation of CYP3A4 upon rifampicin treatment. We utilized the PXR-regulated 
luciferase reporter cell line (reporter-HepG2) to analyze induction of target gene 
expression. We have found that pretreatment of PXR-HepG2 cells or human primary 
hepatocytes with 1-2% DMSO greatly enhanced PXR-regulated gene expression. This 
priming effect is both dose- and time-dependent and it can persist up to 48 h.
Results of ChIP assays showed that DMSO decreased acetylation of histone H4 lysine 
12 and increased methylation of H4 arginine 3 in the regulatory region of PXR target 
gene CYP3A4. PRMT1 is important in the priming process. Overexpression of PRMT1 
enhanced the priming effect while knockdown of PRMT1 reduced it. Prior inhibition of 
methyltransferase activity by ADOX or inhibition of histone deacetylase by TSA 
abolished the priming effect. Based on these observations and other reports (50,286), we 
proposed a model of “Relay between histone methylation and acetylation on the 
transcription cycle” that transcription cycle begins with deacetylation of specific lysine 
residue, such as H4K12 which facilitates methylation of histone (e.g. H4R3). This 
methylation in turn facilitates the total histone acetylation.  
DMSO treatment has other effects on HepG2 cells including a G0/G1 cell arrest. Other 
responses to DMSO are currently being investigated.   
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